

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 September 2003 (18.09.2003)

PCT

(10) International Publication Number
WO 03/076417 A2

- (51) International Patent Classification⁷: **C07D 239/91**
- (21) International Application Number: **PCT/EP03/02277**
- (22) International Filing Date: 6 March 2003 (06.03.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
PCT/EP02/03240 8 March 2002 (08.03.2002) EP
- (71) Applicant (for all designated States except US):
WARNER-LAMBERT COMPANY LLC [US/US];
201 Tabor Road, Morris Plains, NJ 07950 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **GAUDILLIERE, Bernard** [FR/FR]; 28, rue de Zilina, F-92000 Nanterre (FR). **JACOBELLI, Henry** [FR/FR]; 65, avenue du Général de Gaulle, F-91550 Paray Vieille Poste (FR). **KOSTLAN, Catherine** [US/US]; 9876 Moon Road, Saline, MI 48176 (US). **LI, Jack** [US/US]; 258 Village Green Blvd., #101, Ann Arbor, MI 48105 (US). **YUE, Wen-Song** [US/US]; 6015 Gabrielle Ave, Ann Arbor, MI 48103 (US).
- (74) Agents: **HIRSCH, Denise et al.**; Pfizer, Global Research and Development, Fresnes Laboratories, 3-9, rue de la Loge, B.P. 100, F-94265 Fresnes Cedex (FR).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,

[Continued on next page]

(54) Title: OXO-AZABICYCLIC COMPOUNDS




A2




(1)




(i/a)



(i/b)



(i/c)



(i/d)

(57) Abstract: A compound selected from those of formula (1): ~',Xi Gi X 2 (7l) I ,N'R₁ (I) 11 - G 2 X3 wherein: 5 • X,, X2, and X3, represent N or -CR3 in which R3 is as described in the description, • G, represents a group selected from those of formulae (i/a) and (i/b): R4 R6, R4 N (i/a) (i/b) in which R4, R5, and R6 are as defined in the description, • G2 represents a group selected from carbon-carbon triple bond, -CH=C=CH-, C=O, 10 C=S, S(O)_n, in which n1 represents an integer from 0 to 2 inclusive, or a group of formula (i/c): 11-1y -r (i/c), Y1 in which Y1 represents O, S, -NH or -Nalkyl, and Y2 represents O, S, -NH or -Nalkyl, • n is an integer from 0 to 6 inclusive, and m is an integer from 0 to 7 inclusive, 15 • Z, represents -CRgR,o, wherein R9 and R,o areas defined in the description, • A represents a ring system, • R, represents a group selected from H, alkyl, alkenyl, alkynyl, optionally substituted and the group of formula (i/d) (G3)q~(Z2)~ (i/d) 20 in which p, Z2, B, q and G3 are as defined in the description and optionally, its optical isomers, N-oxide, and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same are useful as specific inhibitors of type-13 matrix metalloprotease.



GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR),
OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG)

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

Published:

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

TITLE OF THE INVENTION

Oxo-azabicyclic compounds

FIELD OF THE INVENTION

The present invention relates to novel oxo azabicyclic compounds which are useful for preparing medicinal products for treating complaints involving a therapy with a matrix metalloprotease-13 (MMP-13) inhibitor. These medicinal products are useful in particular for treating certain inflammatory conditions such as rheumatoid arthritis or osteoarthritis, as well as certain proliferative conditions such as cancers.

TECHNOLOGICAL BACKGROUND OF THE INVENTION

Matrix metalloproteases (MMPs) are enzymes which are involved in the renewal of extracellular matrix tissue, such as cartilage, tendons and joints. MMPs bring about the destruction of the extracellular matrix tissue, which is compensated for, in a non-pathological physiological state, by its simultaneous regeneration.

Under normal physiological conditions, the activity of these extremely aggressive peptidases is controlled by specialized proteins which inhibit MMPs, such as the tissue inhibitors of metalloprotease (TIMPs).

Local equilibrium of the activities of MMPs and of TIMPs is critical for the renewal of the extracellular matrix. Modifications of this equilibrium which result in an excess of active MMPs, relative to their inhibitor, induce a pathological destruction of cartilage, which is observed in particular in rheumatoid arthritis and in osteoarthritis.

In pathological situations, an irreversible degradation of articular cartilage takes place, as is the case in rheumatic diseases such as rheumatoid arthritis or osteoarthritis. In these pathologies, the cartilage degradation process predominates, leading to a destruction of the tissue and resulting in a loss of function.

At least twenty different matrix metalloproteases have been identified to date and are subdivided into four groups, the collagenases, the gelatinases, the stromelysins and the membrane-type MMPs (MT-MMPs), respectively.

Matrix metalloprotease-13 (MMP-13) is a collagenase-type MMP which constitutes the predominant collagenase observed during osteoarthritis, in the course of which pathology the chondrocyte directs the destruction of cartilage.

There is a need for novel MMP inhibitors, more particularly for MMP-13 inhibitors, 5 in order to prevent and/or correct the imbalance in the renewal of extracellular matrix tissue, such as arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary diseases (COPD), age-related macular degeneration (ARMD) and cancer.

10 MMP-inhibitor compounds are known. Most of these MMP-inhibitors are not selective for a single MMP, such as those described by Montana and Baxter (2000) or by Clark et al. (2000).

15 There is also a need in the prior art for novel inhibitors that are active on matrix metalloprotease-13, in order to enrich the therapeutic arsenal that can be used for treating pathologies associated with the destruction of the extracellular matrix and with cancer.

The patent application WO9826664 describes quinazolinone compounds which are used as new antifungal compounds.


20 The compounds of the present application are novel and represent powerful inhibitors of MMP-13. They are consequently of use in the treatment of rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary diseases (COPDs), age-related degeneration (ARMD) and cancer.

25 SUMMARY OF THE INVENTION

The applicant has identified novel oxo azabicyclic compounds that are matrix metalloprotease inhibitors, and more specifically compounds that are selective MMP-13 inhibitors.


More specifically, the present invention relates to compounds of formula (I) :

3



wherein:

- X_1 , X_2 , and X_3 , independently of each other, represent a nitrogen atom or a group $-CR_3$ in which R_3 represents a group selected from hydrogen, (C_1-C_6) alkyl, amino, mono(C_1-C_6)alkylamino, di(C_1-C_6)alkylamino, hydroxy, (C_1-C_6)alkoxy, and halogen, with the proviso that not more than two of the groups X_1 , X_2 and X_3 simultaneously represent a nitrogen atom,
 - G_1 represents a group selected from those of formulae (i/a) and (i/b):



10 in which:

- the carbon atom with number 2 is attached to the group N-R₁ in the ring,
 - R₄ and R₅, identical or different, independently of each other, represent a group selected from hydrogen, (C₁-C₆)alkyl, aryl, aryl(C₁-C₆)alkyl, cycloalkyl, cycloalkyl(C₁-C₆)alkyl, heteroaryl, heteroaryl(C₁-C₆)alkyl, heterocycloalkyl, and heterocycloalkyl(C₁-C₆)alkyl,
 - R₆ represents a group selected from :
 - ✓ hydrogen, trifluoromethyl, OR₇, NR₇R₈, in which R₇ and R₈, identical or different independently of each other, represent hydrogen or (C₁-C₆)alkyl,
 - ✓ (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, aryl, aryl(C₁-C₆)alkyl, cycloalkyl(C₁-C₆)alkyl, heteroaryl, heteroaryl(C₁-C₆)alkyl, heterocycloalkyl, and heterocycloalkyl(C₁-C₆)alkyl, these groups being optionally substituted by one or more groups, which may be identical or different independently of each other, selected from halogen, amino, mono(C₁-C₆)alkylamino, di(C₁-C₆)alkylamino, each alkyl moiety being identical or different independently of each other, cyano,

trihalogeno(C₁-C₆)alkyl, (C₁-C₆)acyl, -C(=O)OR₇, -OR₇ and -SR₇, in which R₇ is as defined hereinbefore,


- G₂ represents a group selected from carbon-carbon triple bond, -CH=C=CH-, C=O, C=S, S(O)_{n1} in which n1 represents an integer from 0 to 2 inclusive, and a group of formula (i/c):



in which the carbon atom with number 1 is attached to the bicyclic compound of formula (I), Y₁ represents a group selected from oxygen, sulphur, -NH and -N(C₁-C₆)alkyl, and Y₂ represents a group selected from oxygen, sulphur, -NH and -N(C₁-C₆)alkyl,

- n represents an integer from 0 to 6 inclusive,
- Z₁ represents -CR₉R₁₀, wherein R₉ and R₁₀, identical or different independently of each other, represent a group selected from hydrogen, (C₁-C₆)alkyl, trihalogeno(C₁-C₆)alkyl, halogen, -OR₇, -SR₇, and -C(=O)OR₇, in which R₇ is as defined hereinbefore, amino, mono(C₁-C₆)alkylamino, di(C₁-C₆)alkylamino in which each alkyl moiety is identical or different independently of each other, and
 - wherein when n is greater than or equal to 2, the hydrocarbon chain Z₁ optionally contains one to two isolated or conjugated multiple bonds,
 - and/or wherein when n is greater than or equal to 2, one of said -CR₉R₁₀ may optionally be replaced with a group selected from oxygen, S(O)_{n1} in which n1 is as defined hereinbefore, -NH and -N(C₁-C₆)alkyl,
- A represents a group selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, these groups being 5- or 6-membered monocycle or bicyclic composed of two 5- or 6-membered monocycle,
- R₁ represents a group selected from :
 - hydrogen,

- (C_1 - C_6)alkyl, (C_2 - C_6)alkenyl, (C_2 - C_6)alkynyl, these groups may be optionally substituted with one or more groups, which may be identical or different independently of each other, selected from amino, cyano, trihalogeno(C_1 - C_6)alkyl, cycloalkyl, $-C(=O)NR_7R_8$, $-C(=O)OR_8$, OR_8 , SR_8 , in which R_7 and R_8 , which may be identical or different independently of each other, represent hydrogen or (C_1 - C_6)alkyl,
- and the group of formula (i/d) :



- ✓ in which p is an integer from 0 to 8 inclusive,
- ✓ Z₂ represents $-CR_{11}R_{12}$ wherein R₁₁ and R₁₂, identical or different independently of each other, represent a group selected from hydrogen, (C_1 - C_6)alkyl, phenyl, trihalogeno(C_1 - C_6)alkyl, halogen, amino, OR₇, SR₇ and $-C(=O)OR_7$ in which R₇ represents hydrogen or (C_1 - C_6)alkyl, and
- wherein when p is greater than or equal to 2, the hydrocarbon chain Z₂ optionally contains one or two isolated or conjugated multiple bonds,
- and/or wherein n is greater than or equal to 2, one of said $-CR_{11}R_{12}$ may optionally be replaced with a group selected from oxygen, S(O)_{n1} in which n1 is as defined hereinbefore, -NH, -N(C_1 - C_6)alkyl, and carbonyl,
- ✓ B represents a group selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, these groups being 5- or 6-membered monocycle or bicyclic composed of two 5- or 6- membered monocycle,
- ✓ q is an integer from 0 to 7 inclusive,
- ✓ the group(s) G₃, which may be identical or different independently of each other, is (are) selected from (C_1 - C_6)alkyl, halogen, CN, NO₂, CF₃, OCF₃, $-(CH_2)_kNR_{13}R_{14}$, $-N(R_{13})C(=O)R_{14}$, $-N(R_{13})C(=O)OR_{14}$, $-N(R_{13})SO_2R_{14}$, $-N(SO_2R_{13})_2$, $-OR_{13}$, $-S(O)_{k1}R_{13}$, $-SO_2-N(R_{13})-(CH_2)_{k2}-NR_{14}R_{15}$, $-(CH_2)_kSO_2NR_{13}R_{14}$, $-X_4(CH_2)_kC(=O)OR_{13}$, $-(CH_2)_kC(=O)OR_{13}$, $-C(=O)O-(CH_2)_{k2}-NR_{13}R_{14}$,

-C(=O)O-(CH₂)_{k2}-C(=O)OR₁₆, -X₄(CH₂)_kC(=O)NR₁₃R₁₄, -(CH₂)_kC(=O)NR₁₃R₁₄, -R₁₇-C(=O)OR₁₃, -X₅-R₁₈, and -C(=O)-R₁₉-NR₁₃R₁₄ in which :

- X₄ represents a group selected from oxygen atom, sulphur atom optionally substituted by one or two oxygen atoms, and nitrogen atom substituted by a hydrogen atom or a (C₁-C₆)alkyl group,

5

- k is an integer from 0 to 3 inclusive,

- k₁ is an integer from 0 to 2 inclusive,

- k₂ is an integer from 1 to 4 inclusive,

10

- R₁₃, R₁₄ and R₁₅, which may be identical or different independently of each other, are selected from hydrogen and (C₁-C₆)alkyl,

- R₁₆ represents a group selected from (C₁-C₆)alkyl, -R₁₉-NR₁₃R₁₄, -R₁₉-NR₁₃-C(=O)-R₁₉-NR₁₄R₁₅, and -C(=O)O-R₁₉-NR₁₃R₁₄ in which R₁₉ represents a linear or branched (C₁-C₆)alkylene group, and R₁₃, R₁₄ and R₁₅ are as defined hereinbefore,

15

-- R₁₇ represents a (C₃-C₆)cycloalkyl group,

- X₅ represents a group selected from single bond, -CH₂-, oxygen atom, sulphur atom optionally substituted by one or two oxygen atoms, and nitrogen atom substituted by hydrogen atom or (C₁-C₆)alkyl group,

- R₁₈ represents a group selected from :

20

o 5- or 6-membered monocycle aryl, heteroaryl, which is optionally substituted by one or more groups, which may be identical or different, selected from (C₁-C₆)alkyl, halogen, hydroxy, cyano, tetrazolyl, amino, and -C(=O)OR₇ wherein R₇ represents hydrogen or (C₁-C₆)alkyl,

o and 5- or 6-membered monocycle cycloalkyl, heterocycloalkyl, which is optionally substituted by one or more groups, which may be identical or different, selected from (C₁-C₆)alkyl, halogen, hydroxy, oxo, cyano, tetrazolyl, amino, and -C(=O)OR₇, wherein R₇ represents hydrogen or (C₁-C₆)alkyl,

5

- m is an integer from 0 to 7 inclusive,
- the group(s) R₂, which may be identical or different independently of each other, is (are) selected from (C₁-C₆)alkyl, halogen, -CN, NO₂, SCF₃, -CF₃, -OCF₃, -NR₇R₈, -OR₈, -SR₈, -SOR₈, -(CH₂)_kSO₂NR₇R₈, -X₇(CH₂)_kC(=O)OR₈, -(CH₂)_kC(=O)OR₈, -X₇(CH₂)_kC(=O)NR₇R₈, -(CH₂)_kC(=O)NR₇R₈, and -X₈-R₂₀ in which:

10 - X₇ represents a group selected from oxygen, sulphur optionally substituted by one or two oxygen atoms, and nitrogen substituted by hydrogen or (C₁-C₆)alkyl,

15 - k is an integer from 0 to 3 inclusive,

- R₇ and R₈, which may be identical or different independently of each other, are selected from hydrogen and (C₁-C₆)alkyl,


20 - X₈ represents a group selected from single bond, -CH₂-, oxygen atom, sulphur atom optionally substituted by one or two oxygen atoms, and nitrogen atom substituted by hydrogen atom or (C₁-C₆)alkyl group,

- R₂₀ represents 5- or 6-membered monocycle aryl, heteroaryl, cycloalkyl, or heterocycloalkyl which is optionally substituted by one or more groups, which may be identical or different, selected from (C₁-C₆)alkyl, halogen, hydroxy and amino, and when the ring is heterocyclic, it comprises from 1 to 4 heteroatoms selected from nitrogen, oxygen and sulphur,

25 optionally, the racemic forms thereof, isomers thereof, N-oxides thereof, and the pharmaceutically acceptable salts thereof.

According to a first embodiment, the invention relates to compounds of formula (I) wherein :

- G_2 represents a group selected from $C=O$, $C=S$, $S(O)_{n1}$ in which $n1$ represents an integer from 0 to 2 inclusive, or a group of formula (i/c):



5

in which the carbon atom with number 1 is attached to the bicycle of the compound of formula (I), Y_1 represents a group selected from oxygen, sulphur, -NH and $-N(C_1-C_6)alkyl$, and Y_2 represents a group selected from oxygen, sulphur, -NH and $-N(C_1-C_6)alkyl$,

- $X_1, X_2, X_3, G_1, n, Z_1, A, R_1, m$ and R_2 are as defined in formula (I).

10 According to a second embodiment, the invention relates to compounds of formula (I) wherein :

- G_2 represents a carbon-carbon triple bond,
- n represents an integer from 1 to 6 inclusive,
- $X_1, X_2, X_3, G_1, Z_1, A, R_1, m$ and R_2 are as defined hereinbefore.

15 According to a third embodiment, the invention relates to compounds of formula (I) wherein :

- G_2 represents a carbon-carbon triple bond,
- n is zero,
- Z_1 is absent,


20 • A represents a group selected from heteroaryl, cycloalkyl, heterocycloalkyl, these groups being 5- or 6-membered monocycle or bicycle composed of two 5- or 6- membered monocycle,

- $X_1, X_2, X_3, G_1, R_1, m$ and R_2 are as defined hereinbefore.

According to a fourth embodiment, the invention relates to compounds of formula (I) 25 wherein :

- G_2 represents a carbon-carbon triple bond,
- n is zero,


- Z_1 is absent,
- A represents a phenyl group,
- R_1 represents a hydrogen atom or a group of formula (i/d) :



- 5 ✓ in which p is an integer from 0 to 8 inclusive,
- ✓ Z_2 represents $-CR_{11}R_{12}$ wherein R_{11} and R_{12} , identical or different independently of each other, represent a group selected from hydrogen, (C_1 - C_6)alkyl, phenyl, trihalogeno(C_1 - C_6)alkyl, halogen, amino, OR_7 , SR_7 and $-C(=O)OR_7$ in which R_7 represents hydrogen or (C_1 - C_6)alkyl, and
- 10 - wherein when p is greater than or equal to 2, the hydrocarbon chain Z_2 optionally contains one or two isolated or conjugated multiple bonds,
- and/or wherein n is greater than or equal to 2, one of said $-CR_{11}R_{12}$ may optionally be replaced with a group selected from oxygen, $S(O)_{n1}$ in which $n1$ is as defined hereinbefore, -NH, -N(C_1 - C_6)alkyl, and carbonyl,
- 15 ✓ B represents a phenyl group,
- ✓ q is an integer from 1 to 7 inclusive,
- ✓ the group(s) G_3 , which may be identical or different independently of each other, is (are) selected from $-(CH_2)_kNR_{13}R_{14}$, $-N(R_{13})C(=O)OR_{14}$, $-N(R_{13})SO_2R_{14}$, $-N(SO_2R_{13})_2$, $-S(O)_{k1}R_{13}$, $-SO_2-N(R_{13})-(CH_2)_{k2}-NR_{14}R_{15}$, $-(CH_2)_kSO_2NR_{13}R_{14}$,
- 20 $-X_4(CH_2)_kC(=O)OR_{13}$, $-(CH_2)_kC(=O)OR_{13}$, $-C(=O)O-(CH_2)_{k2}-NR_{13}R_{14}$, $-C(=O)O-(CH_2)_{k2}-C(=O)OR_{16}$, $-X_4(CH_2)_kC(=O)NR_{13}R_{14}$, $-(CH_2)_kC(=O)NR_{13}R_{14}$, $-R_{17}-C(=O)OR_{13}$, $-X_5-R_{18}$, $-C(=O)-R_{19}-NR_{13}R_{14}$ and $-X_6-R_{21}$ in which :
- X_4 represents a group selected from oxygen atom, sulphur atom optionally substituted by one or two oxygen atoms, and nitrogen atom substituted by a hydrogen atom or a (C_1 - C_6)alkyl group,
- 25 - k is an integer from 0 to 3 inclusive,
- $k1$ is an integer from 1 to 2 inclusive,
- $k2$ is an integer from 1 to 4 inclusive,
- R_{13} , R_{14} and R_{15} , which may be identical or different independently of each other, are selected from hydrogen and (C_1 - C_6)alkyl,


- R_{16} represents a group selected from $(C_1-C_6)alkyl$, $-R_{19}-NR_{13}R_{14}$, $-R_{19}-NR_{13}-C(=O)-R_{19}-NR_{14}R_{15}$, and $-C(=O)O-R_{19}-NR_{13}R_{14}$ in which R_{19} represents a linear or branched $(C_1-C_6)alkylene$ group, and R_{13} , R_{14} and R_{15} are as defined hereinbefore,
- 5 - R_{17} represents a $(C_3-C_6)cycloalkyl$ group,
- X_5 represents a group selected from single bond, $-CH_2-$, oxygen atom, sulphur atom optionally substituted by one or two oxygen atoms, and nitrogen atom substituted by hydrogen atom or $(C_1-C_6)alkyl$ group,
- R_{18} represents a group selected from heteroaryl, cycloalkyl, heterocycloalkyl, these groups being 5- or 6-membered monocycle or bicyclic composed of two 5- or 6- membered monocycle, which is optionally substituted by one or more groups, which may be identical or different independently of each other, selected from $(C_1-C_6)alkyl$, halogen, hydroxy, oxo, cyano, tetrazolyl, amino, and $-C(=O)OR_7$ wherein R_7 represents hydrogen or $(C_1-C_6)alkyl$,
- 10 - X_6 represents a group selected from $-CH_2-$, sulphur atom optionally substituted by one or two oxygen atoms, and nitrogen atom substituted by hydrogen atom or $(C_1-C_6)alkyl$ group,
- R_{21} represents a phenyl group which is optionally substituted by one or more groups, which may be identical or different independently of each other, selected from $(C_1-C_6)alkyl$, halogen, hydroxy, cyano, tetrazolyl, amino, and $-C(=O)OR_7$ wherein R_7 represents hydrogen or $(C_1-C_6)alkyl$,
- 15 • and X_1 , X_2 , X_3 , G_1 , m and R_2 are as defined in formula (I).

The substituent R_1 that is preferred according to the invention is the group of formula (i/d):




25 wherein Z_2 , p , B , G_3 and q are as defined in the compound of formula (I).

More particularly, the substituent R_1 that is preferred according to the invention is the group of formula (i/d):




wherein Z_2 represents a group $-CR_{11}R_{12}$ in which R_{11} and R_{12} represents each a hydrogen atom., and p, B, G_3 and q are as defined in the compound of formula (I).

- 5 More particularly, the substituent R_1 that is preferred according to the invention is the group of formula (i/d):



wherein p is one, and Z_2 , B, G_3 and q are as defined in the compound of formula (I).

- 10 More particularly, the substituent R_1 that is preferred according to the invention is the group of formula (i/d):



- 15 wherein B represents a phenyl group, q is equal to 0 or 1, and G_3 , when it is present, represents a group selected from OR_{13} , halogen, $S(O)_{k1}R_{13}$ and $(CH_2)_kC(=O)OR_{13}$ in which R_{13} represents an hydrogen atom or a (C_1-C_6) alkyl group, k is zero, and k_1 is two, and Z_2 , p are as defined in the compound of formula (I).

- 20 The invention relates also to the compounds of formula (I) wherein G_1 represents a group of formula (i/a) in which R_4 represents a hydrogen atom or a methyl group, or a group of formula (i/b) in which R_4 and R_5 , identical, represent each a hydrogen atom or a methyl group, and R_6 represents a hydrogen atom or a methyl group, and X_1 , X_2 , X_3 , G_2 , Z_1 , n, m and R_2 are as defined in formula (I).

Preferred compounds of the invention are compounds of formula (I) wherein X_1 represents a group $-CR_3$ in which R_3 represents a hydrogen atom, X_2 represents a nitrogen atom or a group $-CR_3$ in which R_3 represents a hydrogen atom, and X_3 represents a group $-CR_3$ in which R_3 represents a hydrogen atom.

Other preferred compounds of the invention are compounds wherein G_2 represents a carbon-carbon triple bond or a group of formula (i/c) in which Y_1 represents an oxygen atom, and Y_2 represents a group $-NH$.

Still more preferred compounds of the invention are those compounds of formula (I) 5 wherein Z_1 represents $-CR_9R_{10}$ in which R_9 and R_{10} represent each a hydrogen atom, and n is one.

Especially preferred compounds of the invention are compounds wherein A represents a group selected from phenyl and pyridyl, m is zero or one, and R_2 represents a (C_1-C_6)alkoxy group or a hydrogen atom.

10 More particularly, the invention relates to the following compounds of formula (I) :

- 3-(4-methoxy-benzyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid 4-methoxybenzylamide
- 3-(4-methoxy-benzyl)-2-methyl-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid 4-methoxy-benzylamide, hydrochloride
- 3-(4-methoxy-benzyl)-1-methyl-4-oxo-1,2,3,4-tetrahydro-quinazoline-6-carboxylic acid 4-methoxy-benzylamide
- 3-(4-methoxy-benzyl)-1,2,2-trimethyl-4-oxo-1,2,3,4-tetrahydro-quinazoline-6-carboxylic acid 4-methoxy-benzylamide
- 4-[6-(4-methoxy-benzylcarbamoyl)-4-oxo-1,4-dihydro-2H-quinazolin-3-ylmethyl]-20 benzoic acid
- 4-[6-(4-methoxy-benzylcarbamoyl)-1-methyl-4-oxo-1,4-dihydro-2H-quinazolin-3-ylmethyl]-benzoic acid methyl ester
- 4-[6-(4-methoxy-benzylcarbamoyl)-1-methyl-4-oxo-1,4-dihydro-2H-quinazolin-3-ylmethyl]-benzoic acid,
- 3-(4-fluoro-benzyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid 3-methoxybenzylamide
- 3-(4-methanesulfonyl)-benzyl-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid 4-methoxy-benzylamide

- 4-Oxo-3-[4-(pyrrolidine-1-sulfonyl)-benzyl]-3,4-dihydro-quinazoline-6-carboxylic acid 4-methoxy-benzylamide
- 4-[6-(3-methoxy-benzylcarbamoyl)-4-oxo-4H-quinazolin-3-ylmethyl]-benzoic acid,
- 3-(4-fluoro-benzyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid (2-methoxy-
5 pyridin-4-ylmethyl)-amide,
- 3-(3-fluoro-benzyl)-4-oxo-3,4-dihydro-pyrido[3,4-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide,
- and 3-(3-fluoro-benzyl)-4-oxo-3,4-dihydro-pyrido[3,4-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide
10

10

Further preferred compounds are:

- 3-(3,4-Difluoro-benzyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide
- 3-(3,4-Difluoro-benzyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid 4-methoxy-
15 benzylamide.

More particularly, the invention relates also to the following compounds of formula (I) :

- 3-(4-fluorobenzyl)-6-(3-phenyl-prop-1-ynyl)-3 H-quinazolin-4-one,
- methyl 4-[4-oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzoate,
- 4-[4-oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzoic acid,
- 3-(4-fluorobenzyl)-6-(3-phenyl-prop-1-ynyl)-3H-pyrido[3,4-d]pyrimidin-4-one,
20
- methyl 4-[6-(3-phenyl-prop-1-ynyl)-4-oxo-4H-pyrido[3,4-d]pyrimidin-3-ylmethyl]-benzoate,
- 4-[6-(3-phenyl-prop-1-ynyl)-4-oxo-4H-pyrido[3,4-d]pyrimidin-3-ylmethyl]-benzoic acid,
- 4-[4-oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazoline-3-ylmethyl]-benzoic acid,
25
- 4-{6-[3-(4-methoxy-phenyl)-prop-1-ynyl]-4-oxo-4H-quinazoline-3-ylmethyl}-benzoic acid,
- 4-[4-oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazoline-3-ylmethyl]-benzamide
- and 3-[(3,5-difluoro-4-hydroxy)-benzyl]-6-(3-phenyl-prop-1-ynyl)-3H-quinazolin-4-one.
30

Further preferred compounds are:

- 4-[6-(3-Imidazol-1-yl-prop-1-ynyl)-4-oxo-4H-quinazolin-3-ylmethyl]-benzoic acid
- 4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzenesulfonamide
- 4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzonitrile
- 5 - 3-(3-Chloro-benzyl)-6-(4-phenyl-but-1-ynyl)-3H-quinazolin-4-one
- 3-(3-Chloro-benzyl)-6-(3-phenyl-prop-1-ynyl)-3H-quinazolin-4-one
- 4-[4-Oxo-6-(3-pyrazol-1-yl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzoic acid
- 6-(3-Phenyl-prop-1-ynyl)-3-[4-(1H-tetrazol-5-yl)-benzyl]-3H-quinazolin-4-one
- 3-(3,4-Difluoro-benzyl)-6-[3-(pyridin-4-yloxy)-prop-1-ynyl]-3H-quinazolin-4-one
- 10 - 3-(3,4-Difluoro-benzyl)-6-[3-(4-methoxy-phenyl)-prop-1-ynyl]-3H-quinazolin-4-one
- N-{4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-phenyl}-acetamide
- 3-(3,4-Difluoro-benzyl)-6-(3-phenyl-prop-1-ynyl)-3H-quinazolin-4-one
- 3-(4-Acetyl-benzyl)-6-[3-(4-methoxy-phenyl)-prop-1-ynyl]-3H-quinazolin-4-one
- 6-(3-Phenyl-prop-1-ynyl)-3-pyridin-4-ylmethyl-3H-quinazolin-4-one
- 15 - 6-[3-(4-Methoxy-phenyl)-prop-1-ynyl]-3-pyridin-4-ylmethyl-3H-quinazolin-4-one

Most preferred are the compounds listed in the table below, which refers to the examples later in the application.

Ex. 9		Methyl 4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]benzoate
Ex. 10, 18		4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]benzoic acid
Ex. 17		4-[6-(3-Methoxy-benzylcarbamoyl)-4-oxo-4H-quinazolin-3-ylmethyl]benzoic acid
Ex. 19		4-[6-(3-(4-Methoxy-phenyl)-prop-1-ynyl)-4-oxo-4H-quinazoline-3-ylmethyl]benzoic acid

Ex. 23		3-(3-Fluoro-benzyl)-4-oxo-3,4-dihydro-pyrido[3,4-d]pyrimidine-6 carboxylic acid 3-methoxy-benzylamide
Ex. 24		3-(3-Fluoro-benzyl)-4-oxo-3,4-dihydro-pyrido[3,4-d]pyrimidine-6 carboxylic acid 4-methoxy-benzylamide
Ex. 58		4-[6-(3-Imidazol-1-yl-prop-1-ynyl)-4-oxo-4H-quinazolin-3-ylmethyl]-benzoic acid
Ex. 59		4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzenesulfonamide
Ex. 60		4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzonitrile
Ex. 64		6-(3-Phenyl-prop-1-ynyl)-3-[4-(1H-tetrazol-5-yl)-benzyl]-3H-quinazolin-4-one
Ex. 65		3-(3,4-Difluoro-benzyl)-6-[3-(pyridin-4-yloxy)-prop-1-ynyl]-3H-quinazolin-4-one
Ex. 66		3-(3,4-Difluoro-benzyl)-6-[3-(4-methoxy-phenyl)-prop-1-ynyl]-3H-quinazolin-4-one
Ex. 67		N-{4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-phenyl}-acetamide
Ex. 69		3-(4-Acetyl-benzyl)-6-[3-(4-methoxy-phenyl)-prop-1-ynyl]-3H-quinazolin-4-one

Ex. 70		6-(3-Phenyl-prop-1-ynyl)-3-pyridin-4-ylmethyl-3H-quinazolin-4-one
Ex. 71		6-[3-(4-Methoxy-phenyl)-prop-1-ynyl]-3-pyridin-4-ylmethyl-3H-quinazolin-4-one

The optical isomers, the N-oxides, as well as the addition salts with a pharmaceutically-acceptable acid or base, of the preferred compounds form an integral part of the invention.

5 The invention also relates to a pharmaceutical composition comprising as active ingredient an effective amount of a compound of formula (I) together with one or more pharmaceutically-acceptable excipients or carriers.

Another embodiment of the invention concerns the use of the compound of formula (I) for the preparation of a medicinal product intended for treating a disease involving therapy by 10 inhibition of matrix metalloprotease, and more particularly of type-13 matrix metalloprotease.

The invention also relates to a method for treating a living body afflicted with a disease involving a therapy by inhibition of matrix metalloprotease, and more particularly of type-13 matrix metalloprotease, the said method comprising the administration of an effective 15 amount of a compound of formula (I) to a patient in need thereof.

A preferred method of treatment according to this invention is treatment of a disease selected from arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary diseases, age-related degeneration 20 and cancers.

More particularly, a preferred method of treatment according to this invention is treatment of disease selected from arthritis, osteoarthritis and rheumatoid arthritis.

DETAILED DESCRIPTION OF THE INVENTION

The compounds provided by this invention are those defined in formula (I). In formula (I), it is understood that :

- a (C_1-C_6)alkyl group denotes a linear or branched group containing from 1 to 6 carbon atoms ; example of such groups, without implying any limitation are methyl, ethyl, propyl, isopropyl, tert-butyl, neopentyl, hexyl,

- a (C_2-C_6)alkenyl group denotes a linear or branched group containing from 2 to 6 carbon atoms, and one or more double bonds ; examples of such groups without implying any limitation are vinyl, allyl, 3-buten-1-yl, 2-methyl-buten-1-yl, hexenyl,

- a (C_2-C_6)alkynyl group denotes a linear or branched group containing from 2 to 6 carbon atoms, and one or more triple bonds ; examples of such groups without implying any limitation are ethynyl, propynyl, 3-butyn-1-yl, 2-methyl-butyn-1-yl, hexynyl,

- a (C_1-C_6)alkoxy group means the alkyl group as mentioned above bound through an oxygen atom ; examples of such compounds without implying any limitation are methoxy, ethoxy, *n*-propyloxy, *tert*-butyloxy,

- a mono(C_1-C_6)alkylamino denotes a amino group substituted by one (C_1-C_6)alkyl group as defined hereinbefore ; example of such groups, without implying any limitation are methyl amino, isobutyl amino, ethylamino,

- a di(C_1-C_6)alkylamino denotes a amino group substituted by two (C_1-C_6)alkyl groups as defined hereinbefore, each alkyl group being identical or different ; example of such groups, without implying any limitation are dimethylamino, diethylamino,

- an aryl group denotes an aromatic monocyclic or bicyclic system containing from 5 to 10 carbon atoms, and in the case of a bicyclic system, one of the ring of which is aromatic in character, and the other ring of which may be aromatic or partially hydrogenated ; examples of such groups without implying any limitation are, phenyl, naphthyl, indenyl, benzocyclobutenyl,

- a heteroaryl group denotes an aryl group as described above in which 1 to 4 carbon atoms are replaced by 1 to 4 hetero atoms selected from oxygen, sulfur and nitrogen ; examples of such groups without implying any limitation are furyl, thienyl, pyrrolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, benzofuryl, benzothienyl, indolyl, quinolyl,

isoquinolyl, benzodioxolyl, benzodioxinyl, benzo[1,2,5]thiadiazolyl,
benzo[1,2,5]oxadiazolyl,

- a cycloalkyl group denotes a monocyclic or bicyclic system containing from 3 to 10 carbon atoms, this system being saturated or partially unsaturated but without aromatic character ; examples of such groups without implying any limitation are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl, cycloheptyl, adamantyl, decalinyl, norbornyl,

- a heterocycloalkyl group denotes a cycloalkyl group as defined hereinbefore in which 1 to 4 carbon atoms are replaced by 1 to 4 hetero atoms selected from oxygen, sulfur, and nitrogen,

- a bicycle denotes two fused-monocycle and,
- a trihalogeno(C₁-C₆)alkyl group denotes an alkyl group as defined above which contains a trihalogeno group ; examples of such groups without implying any limitation are trifluoromethyl, 2,2,2-trifluoroethyl,

- a (C₁-C₇)acyl group denotes an alkyl group or a aryl group as defined above bound through a carbonyl group ; examples of such groups without implying any limitation are acetyl, ethylcarbonyl, benzoyl,

- a multiple bond denotes double bond or triple bond,
- a halogen atom means fluoro, chloro, bromo or iodo,
- optical isomers refer to racemates, enantiomers and diastereoisomers.

The invention also relates to the pharmaceutically acceptable salts of the compounds of formula (I). A review of the pharmaceutically acceptable salts will be found in *J. Pharm. Sci.*, 1977, 66, 1-19.


Pharmaceutically acceptable acids mean non-toxic salts derived from mineral or organic acids. Among those there may be mentioned, without implying any limitation, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphonic acid, nitric acid, citric acid, acetic acid, trifluoroacetic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, tartaric acid, maleic acid, ascorbic acid, oxalic acid, methanesulfonic acid, camphoric acid, benzoic acid, toluenesulfonic acid, etc...

Pharmaceutically acceptable bases mean non-toxic salts derived from mineral or organic bases. Among those, there may be mentioned, without implying any limitation, sodium

hydroxide, potassium hydroxide, calcium hydroxide, triethylamine, tert-butylamine, dibenzylethylenediamine, piperidine, pyrrolidine, benzylamine, quaternary ammonium hydroxides etc...

The invention also relates to a process for the preparation of compounds of formula (I),


5 which uses as starting material a compound of formula (II):



in which X₁, X₂, X₃, and Y₁ have the same definitions as the compound of formula (I), and

T represents a group (C₁-C₆)alkyl,


compound of formula (II) which is treated with a compound of formula (III):



10

in which Z₁, Y₂, R₂, A, n and m have the same definitions as the compound of formula (I),

by activating the acid function with an activator, in the presence of diisopropylethylamine and a solvent, to yield the compound of formula (IV) :



15


in which X₁, X₂, X₃, Y₁, T, Z₁, Y₂, R₂, A, n and m are as defined hereinbefore,

compound of formula (IV) in which the ester group is hydrolyzed and the subsequently compound obtained is then treated with an activator in the presence of a base and a primary amine with the general formula R₁-NH₂ in which R₁ is as defined in the compound of formula (I),

20

to yield the compound of formula (V) :


20



in which X_1 , X_2 , X_3 , Y_1 , Y_2 , Z_1 , R_2 , R_1 , A , n and m are as defined hereinbefore,


which compound of formula (V) is treated :

- either with triethyl orthoformate under heating condition, to yield the compound of formula (I/a), which is a particular case of the compound of formula (I):




in which X_1 , X_2 , X_3 , Y_1 , Y_2 , Z_1 , R_2 , R_1 , A , n and m are as defined hereinbefore,

- or under heating condition in the presence of acid, with a compound of formula (VI):




- 10 in which R_4 has the same definition as the compound of formula (I),
to yield the compound of formula (I/b), which is a particular case of the compound of
formula (I):




in which X_1 , X_2 , X_3 , Y_1 , Y_2 , Z_1 , R_2 , R_1 , R_4 , A , n and m are as defined hereinbefore,

- 15 • or with a compound of formula (VII) in basic condition:



in which R_4 and R_5 have the same definition as the compound of formula (I),

to yield the compound of formula (I/c), which is a particular case of the compound of formula (I):




in which X_1 , X_2 , X_3 , Y_1 , Y_2 , Z_1 , R_2 , R_1 , R_4 , R_5 , A , n and m are as defined hereinbefore.

- which compound of formula (I/c) is optionally treated with a hydride, in the presence of a compound of formula (VIII):



in which R₆ has the same definition as the compound of formula (I),

- to yield the compound of formula (I/d), which is a particular case of the compound of
10 formula (I):




in which X_1 , X_2 , X_3 , Y_1 , Y_2 , Z_1 , R_2 , R_1 , R_4 , R_5 , R_6 , A , n and m are as defined hereinbefore,


- compounds of formulae (I/a), (I/b), (I/c) and (I/d) constitute some compounds of the invention, which are purified, where appropriate, according to a conventional purification technique, which are separated, where appropriate, into their different isomers according to a conventional separation technique, and which are converted, where appropriate, into addition salts thereof with a pharmaceutically-acceptable acid or base, or into N-oxide thereof.

- The invention also relates to a process for the preparation of compounds of formula (I),
which uses as starting material a compound of formula (X):

22




in which X_1 , X_2 , and X_3 have the same definitions as the compound of formula (I), and Hal represents a halogen atom,
 5 which compound of formula (X) is treated in a first step with a derivate of phosgene to yield the compound of formula (XI):




in which X_1 , X_2 , X_3 and Hal are as defined hereinbefore,
 10 which compound of formula (XI) is treated in basic medium with a primary amine of general formula $\text{R}_1\text{-NH}_2$ in which R_1 has the same definition as in the compound of formula (I),

to yield the compound of formula (XII):




in which X_1 , X_2 , X_3 , R_1 and Hal are as defined hereinbefore,
 15 which compound of formula (XII) is treated:

- either with triethyl orthoformate under heating condition, to yield the compound of formula (XIII/a) :




in which X_1 , X_2 , X_3 , R_1 and Hal are as defined hereinbefore,

- or under heating condition in the presence of an acid, with a compound of formula (VI):




- 5 in which R_4 has the same definition as the compound of formula (I),
to yield the compound of formula (XIII/b) :




in which X_1 , X_2 , X_3 , Hal , R_1 and R_4 are as defined hereinbefore,

- or with a compound of formula (VII) in basic conditions:



- 10 in which R_4 and R_5 have the same definition as the compound of formula (I),
to yield the compound of formula (XIII/c) :




in which X_1 , X_2 , X_3 , Hal , R_1 , R_4 and R_5 are as defined hereinbefore,

- 15 which compound of formula (XIII/c) is optionally treated with a hydride, in the presence of
a compound of formula (VIII):




in which R_6 has the same definition as the compound of formula (I), and Hal is a halogen atom,

to yield the compound of formula (XIII/d), which is a particular case of the compound of formula (I):




in which X_1 , X_2 , X_3 , Hal, R_1 , R_4 , R_5 and R_6 are as defined hereinbefore,

- 5 all compounds of formulae (XIII/a), (XIII/b), (XIII/c) and (XIII/d) constitute the compound of formula (XIII/e):




in which X_1 , X_2 , X_3 , Hal, R_1 and G_1 are as defined in the compound of formula (I),

- 10 compound of formula (XIII/e) which is treated under conditions of palladium-catalyzed alkynylation with a compound of formula (XIV):



in which Z_1 , R_2 , A , n and m have the same definitions as the compound of formula (I),

- to yield the compound of formula (I/e), which is a particular case of the compound of formula (I):




- 15 in which X_1 , X_2 , X_3 , R_1 , G_1 , Z_1 , R_2 , A , n and m have the same definitions as the compound of formula (I),

compounds of formula (I/e) constitute some compounds of the invention, which are purified, where appropriate, according to a conventional purification technique, which are separated, where appropriate, into their different isomers according to a conventional separation technique, and which are converted, where appropriate, into addition salts thereof with a pharmaceutically-acceptable acid or base, or into N-oxide thereof.

An alternative way to obtain the compound of formula (XIII/a) from compound of formula (XI) is described in the following scheme 1:


10

Scheme 1

Wherein X_1 , X_2 , X_3 , R_1 and Hal, are as defined above.


In a first step, compound of formula (XI) is treated with an aqueous solution of ammonium hydroxide to yield compound of formula (XI/a) which is reacted with triethyl orthoformate in the presence of a catalytic amount of acid like *para*-toluene sulfonic acid (PTSA). The 3*H*-quinazolin-4-one (XI/b) obtained is condensed in basic medium to a compound of formula R_1 -Hal, in which R_1 is as defined in the compound of formula (I) and Hal represents a halogen, to yield the compound of formula (XIII/a).

The invention also relates to a process for the preparation of compounds of formula (I), which uses as starting material a compound of formula (XIII/e) :




in which X_1 , X_2 , X_3 , R_1 and G_1 are as defined in the compound of formula (I), and Hal is a halogen atom,

compound of formula (XIII/e) which is condensed, in the presence of
5 dichlorobis(triphenylphosphine)palladium, copper iodide and *N,N'*-diisopropylethylamine
in dimethylformamide, on a compound of formula (XV) :



in which Z_1 , R_2 , A , n and m have the same definitions as the compound of formula (I),


to yield the compound of formula (I/e), which is a particular case of the compound of
10 formula (I):



in which X_1 , X_2 , X_3 , R_1 , G_1 , Z_1 , R_2 , A , n and m have the same definitions as the compound
of formula (I).


The invention also relates to a process for the preparation of compounds of formula (I),

which uses as starting material a compound of formula (XIII/e) :




in which X_1 , X_2 , X_3 , R_1 and G_1 are as defined in the compound of formula (I), and Hal is a
halogen atom,

compound of formula (XIII/e) which is reacted with carbon monoxide in an alkaline medium in the presence of a protic solvent like methanol and a catalytic amount of palladium , to yield the compound of formula (XVI):



5 in which X_1 , X_2 , X_3 , R_1 and G_1 are as defined in the compound of formula (I),

compound of formula (XVI) which is hydrolysed under basic medium to yield the compound of formula (XVII):




10 in which X_1 , X_2 , X_3 , R_1 and G_1 are as defined in the compound of formula (I),

compound of formula (XVII) which is condensed under basic medium in the presence of a Mukayama reagent, on the compound of formula (XVIII):



15 in which Z_1 , R_2 , A , n and m have the same definitions as the compound of formula (I),

to yield the compound of formula (I/f), which is a particular case of the compound of formula (I):




20 in which X_1 , X_2 , X_3 , Z_1 , R_2 , R_1 , A , n and m are as defined hereinbefore,

compounds of formula (I/f) constitute some compounds of the invention, which are purified, where appropriate, according to a conventional purification technique, which are separated, where appropriate, into their different isomers according to a conventional

separation technique, and which are converted, where appropriate, into addition salts thereof with a pharmaceutically-acceptable acid or base, or into N-oxide thereof.

The invention also relates to a process for the preparation of compounds of formula (I),


5 which uses as starting material a compound of formula (XIX) :



in which Hal represents a halogen atom,

compound of formula (XIX) which is heated in the presence of formamidine acetate in a


10 polar solvent like 2-methoxyethan-1-ol, to yield the compound of formula (XX):



in which Hal is as defined hereinbefore,


compound of formula (XX) which is treated in basic medium with a compound of formula

15 R₁-Hal, in which R₁ is as defined in the compound of formula (I) and Hal represents a halogen atom, to yield the compound of formula (XXI):



in which Hal and R₁ are as defined hereinbefore,


20 compound of formula (XXI) which is reacted with carbon monoxide under basic medium in the presence of an alcoholic solvent like methanol and a catalytic amount of palladium like PdCl₂(dpdpf), to yield the compound of formula (XXII):



in which R_1 is as defined hereinbefore,

compound of formula (XXII) which is condensed, in the presence of trimethylaluminium,


5 with a compound of formula (XVIII):



in which Z_1 , R_2 , A , n and m have the same definitions as the compound of formula (I),

to yield the compound of formula (I/g), which is a particular case of the compound of

10 formula (I):



in which Z_1 , R_2 , R_1 , A , n and m are as defined hereinbefore,

compounds of formula (I/g) constitute some compounds of the invention, which are

purified, where appropriate, according to a conventional purification technique, which are

15 separated, where appropriate, into their different isomers according to a conventional

separation technique, and which are converted, where appropriate, into addition salts

thereof with a pharmaceutically-acceptable acid or base, or into N-oxide thereof.

The compounds of the invention that are present in the form of a mixture of

20 diastereoisomers are isolated in a pure form by using conventional separation techniques

such as chromatography.

As mentioned above, compounds of formula (I) of the present invention are matrix metalloprotease inhibitors, and more particularly inhibitors of the enzyme MMP-13.

In this respect, their use is recommended for the treatment of diseases or complaints involving a therapy by MMP-13 inhibition. By way of example, the use of the compounds of the present invention may be recommended for the treatment of any pathology in which destruction of extracellular matrix tissue occurs, and most particularly pathologies such as 5 arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary disease, age-related macular degeneration and cancers.

The present invention also relates to pharmaceutical compositions comprising as active 10 ingredient at least one compound of formula (I), an isomer thereof, a N-oxide thereof, or an addition salt thereof with a pharmaceutically-acceptable acid or base, alone or in combination with one or more pharmaceutically-acceptable, inert, non-toxic excipients or carriers.

Among the pharmaceutical compositions according to the invention, there may be 15 mentioned more especially those that are suitable for oral, parenteral (intravenous, intramuscular or subcutaneous), per- or trans-cutaneous, intravaginal, rectal, nasal, perlingual, buccal, ocular or respiratory administration.

Pharmaceutical compositions according to the invention for parenteral injections especially include aqueous and non-aqueous sterile solutions, dispersions, suspension and emulsions, 20 and also sterile powders for reconstituting injectable solutions or dispersions.

Pharmaceutical compositions according to the invention for oral administration in solid form especially include tablets or dragées, sublingual tablets, sachets, gelatin capsules and granules, for oral, nasal, buccal or ocular administration in liquid form, especially include emulsions, solutions, suspensions, drop, syrups and aerosols.

25 Pharmaceutical compositions for rectal or vaginal administration are preferably suppositories, and those for per- or trans-cutaneous administration especially include powders, aerosols, creams, ointment, gels and patches.

The pharmaceutical compositions mentioned hereinbefore illustrate the invention but do not limit it in any way.

Among the pharmaceutically acceptable, inert, non-toxic excipients or carriers there may be mentioned, by way of non-limiting example, diluents, solvents, preservatives, wetting agents, emulsifiers, dispersing agents, binders, swelling agents, disintegrating agents, retardants, lubricants, absorbents, suspending agents, colourants, aromatizing agents etc...
5

The useful dosage varies according to the age and weight of the patient, the administration route, the pharmaceutical composition used, the nature and severity of the disorder and the administration of any associated treatments. The dosage ranges from 2 mg to 1 g per day in
10 one or more administrations. The compositions are prepared by methods that are common to those skilled in the art and generally comprise 0.5% to 60% by weight of active principle (compound of formula (I)) and 40% to 99.5% by weight of pharmaceutically acceptable excipients or carriers.

The examples that follow illustrate the invention but do not limit it in any way.

15 The starting materials used are products that are known or that are prepared according to known operating procedures. The various preparations yield synthetic intermediates that are useful in preparation of the compounds of the invention. Some of these intermediates are new compounds.

20 The structures of the compounds described in the Examples and Preparations were determined according to the usual spectrophotometric techniques (infrared, nuclear magnetic resonance, mass spectrometry, ...)

In the Preparations and Examples, it is understood that :

- DMF means Dimethylformamide,
- THF means tetrahydrofuran,
- DMSO means dimethylsulfoxide,

- TOTU means O-(ethoxycarbonyl)cyanomethylamino]-N-N-N'-N'-tetramethyl uronium fluoroborate,
- DIPEA means diisopropylethylamine.

EXAMPLES


5 **Preparation 1 : 4-Amino-3-[(4-methoxy)-benzylcarbamoyl]-1-carboxylic acid 4-methoxy-benzylamide**

Step 1 : 4-Amino-isophthalic acid

10 6.3 g (150 mmol) of LiOH.H₂O are added to a stirred solution of 15.7 g (75 mmol) of methyl 4-amino-isophthalate in 300 ml of dioxane and 1200 ml of water. The reaction mixture is heated for 1 hour to 100°C, cooled and acidified to pH=1 by the addition of concentrated HCl. A precipitate is obtained then filtered off, washed, and dried under vacuum to yield 13 g (yield = 95.7%) of the desired compound.

N.M.R (DMSO-d₆) ¹H δ (ppm) : 6.80 (d,1H); 6.80-7.80 (bs); 7.80 (dd,1H); 8.35 (s,1H); 11.9-13.1 (bs)

15 **Step 2 : 4-Amino-3-[(4-methoxy)-benzylcarbamoyl]-phenyl-1-carboxylic acid 4-methoxy-benzylamide**




20 2.25 g (16.5 mmol) of 4-methoxybenzylamine, 5.4 g (16.5 mmol) of TOTU and 5.4 ml (3.9 g, 30 mmol) of DIPEA are added successively to a stirred solution of 2.7 g (15 mmol) of the compound obtained in Step 1 to 100 ml of DMF. The reaction mixture is stirred overnight at room temperature, then the solvent is removed under vacuum. The crude mixture is taken up in dichloromethane, and washed successively with HCl 1N and NaOH 1N. After separation by decantation the organic phase is dried over Na₂SO₄ and concentrated under vacuum. The crude product is purified by chromatography and concretized from a mixture of dichloromethane and ether to yield 3.1 g (yield=49.3%) of the desired compound.

N.M.R (DMSO-*d*₆) ¹H δ (ppm) : 3.70 (s,6H) ; 4.35 (t,4H) ; 6.70 (d,1H) ; 6.80-6.90 (m,6H) ; 7.20-7.30 (m,4H) ; 7.65 (dd,1H) ; 8.10 (s,1H) ; 8.45 (t,1H) ; 8.75 (t,1H)

Preparation 2 : Methyl 4-{[2-Amino-5-(4-methoxy-benzylcarbamoyl)-benzoylamino]-methyl}-benzoate

5 *Step 1.: Methyl 6-Amino-N-(4-methoxy-benzyl)-isophthalate*




6.56 g (20 mmol) of TOTU and 2.6 ml (2.74 g, 20 mmol) of 4- methoxybenzylamine are added to a stirred solution of 4.2 g (18.1 mmol) of 4-amino-3-methylcarboxylate-1-phenyl carboxylic acid in 150 ml of anhydrous DMF. The mixture is cooled at 0°C and 9.5 ml (7.02 g, 54.3 mmol) of DIPEA are added. The reaction mixture is stirred overnight at room temperature and concentrated under vacuum. The residue is taken up in 150 ml of dichloromethane, washed with 100ml of a saturated solution of NaHCO₃. The organic layer is dried and concentrated under vacuum. After a chromatography over silica gel 3.5 g (yield=62%) of the desired compound are isolated.

15 TLC : CH₂Cl₂/MeOH 90/10 Rf = 0.80

N.M.R (DMSO-*d*₆) ¹H δ (ppm) : 3.80 (s,3H) ; 3.90 (s,3H) ; 4.55 (d,2H) ; 6.0-6.15 (bs,2H) ; 6.15-6.30 (bs,1H) ; 6.65 (d,1H) ; 6.90 (d,1H) ; 7.25-7.30 (m,2H) ; 7.80 (d,1H) ; 8.25 (s,1H).

PURITY : HPLC = 98.5%

20 *Step 2 : 6-Amino-N-(4-methoxy-benzyl)-isophthalamic acid*




0.3 g (7 mmol) of LiOH, H₂O is added to a stirred solution of 1.1 g (3.5 mmol) of the compound obtained in the preceding Step 2 in 10 ml of dioxane and 40 ml of water. The reaction mixture is heated under reflux for 2 hours, cooled, and acidified at pH=1 by

addition of concentrated HCl. The precipitate obtained is filtered off and dried to give the desired compound.

N.M.R (DMSO-*d*₆) ¹H δ (ppm) : 3.70 (s,3H) ; 4.35 (d,2H) ; 6.75 (d,1H) ; 6.85 (d,2H) ; 7.20 (d,2H) ; 7.75 (dd,1H) ; 8.30 (s1H) ; 8.65 (t,1H).

5 *Step 3 : Methyl 4-[{2-Amino-5-(4-methoxy-benzylcarbamoyl)-benzoylamino]-methyl}-benzoate*




The desired compound is obtained according to the procedure described in the Step 1 of Preparation 2 using as starting material the compound obtained in the preceding step 2 and 10 as reactant the methyl 4-(aminomethyl)benzoate hydrochloride. It is purified by chromatography over silica gel using a mixture of dichloromethane/ether as eluant.

N.M.R (DMSO-*d*₆) ¹H δ (ppm) : 3.70 (s,3H) ; 3.85 (s,3H) ; 4.40 (d,2H) ; 4.50 (d,2H) ; 6.70 (d,1H) ; 6.80-6.90 (m,4H) ; 7.25 (d,2H) ; 7.45 (d,2H) ; 7.70 (dd,1H) ; 7.95 (d,2H) ; 8.15 (s,1H) ; 8.45 (t,1H) ; 8.90 (t,1H).

15 **Preparation 3 : 3-(4-fluorobenzyl)-6-iodo-3H-quinazolin-4-one**


Step 1 : 6-iodo-1H-benzo[a][1,3]oxazine-2,4-dione



To a suspension of 2-amino-5-iodobenzoic acid (4.9 g, 18.0 mmol) in H₂O (20 ml) and concentrated HCl (5 ml) is added dioxane (50 ml) until a clear solution is obtained. Neat diphosgene (5.95 g, 30.0 mmol) is added dropwise (with cooling at times so that the solution would not boil) to give a white precipitate. After stirring at room temperature for 10 min., H₂O (ca. 100 ml) is added and the precipitate is filtered and washed with copious amount of H₂O. It is dried *in vacuo* to give the desired product (5.2 g, quantitative) as white crystals.

N.M.R (DMSO-*d*₆) ¹H δ (ppm) : 6.93 (d, *J* = 8.6 Hz, 1H), 8.00 (dd, *J* = 8.6, 2.0 Hz, 1H), 8.10 (d, *J* = 2.0 Hz, 1H), 11.8 (s, 1H);
 MS (APCI), M/z 288.0 (M - 1).

- *Step 2 : 2-amino-N-(4-fluorobenzyl)-5-iodo-benzamide*



5

To a 50°C solution of the compound obtained in the preceding Step 1(2.1 g, 7.27 mmol) in DMF (20 ml) are added neat 4-fluorobenzylamine (1.18 g, 9.45 mmol) dropwise. The reaction is stirred at room temperature for 10 min. while bubbling is observed (CO₂), and TLC indicated the completion of the reaction. The reaction content is poured into a separatory funnel charged with CH₂Cl₂ and H₂O. After separation, the organic layer is washed with H₂O(3x50 ml) and brine (50 ml). It is dried (Na₂SO₄), filtered and concentrated *in vacuo* to give a white solid which is purified using flash chromatography to give the desired compound as a white solid (2.5 g, 93%).


10

N.M.R (DMSO-*d*₆) ¹H δ (ppm) : 5.15 (d, *J* = 5.8 Hz, 2H), 6.50 (s, 1H), 7.03 (m, 1H); 7.34 (m, 1H), 7.43 (d, *J* = 8.5 Hz, 1H), 8.02 (m, 1H), 8.10 (s, 1H), 8.66 (d, *J* = 1.9 Hz, 1H), 9.18 (t, *J* = 5.8 Hz, 1H);

15

MS (APCI), M/z 371.0 (M + 1).

Step 3 : 3-(4-fluorobenzyl)-6-iodo-3H-quinazolin-4-one



20

To the solution of the compound obtained in the preceding Step 2 (2.69 g, 7.27 mmol) in triethyl orthoformate is added catalytic amount of TsOH. The solution is refluxed for 5h, cooled to room temperature. After removal of all volatiles *in vacuo*, the residue is purified using flash chromatography to give the desired quinazolinone as a brownish solid. Trituration then afforded the desired compound as a white solid (1.56 g, 58%).

25

N.M.R (DMSO-*d*₆) ¹H δ (ppm) : 5.15 (s, 2H), 7.03 (m, 1H); 7.34 (m, 1H), 7.43 (d, *J* = 8.5 Hz, 1H), 8.02 (m, 1H), 8.10 (s, 1H), 8.66 (d, *J* = 1.9 Hz, 1H);

MS (APCI), M/z 381.0 (M + 1).

Preparation 4 : Methyl 4-(6-Iodo-4-oxo-4H-quinazolin-3-ylmethyl)-benzoate

Step 1: Methyl 4-[(2-Amino-5-iodo-benzoylamino)-methyl]-benzoate




5 To a 50°C solution of the compound obtained in the Step 1 of Preparation 3 (1.4 g, 4.84 mmol) in DMF (20 ml) is added the hydrochloride salt of 4-carbomethoxy-benzylamine (1.17 g, 5.8 mmol). The reaction is stirred at room temperature for 1 h while bubbling is observed (CO₂), and TLC indicated the completion of the reaction. The reaction content is poured into a separatory funnel charged with CH₂Cl₂ and H₂O. After separation, the organic layer is washed with H₂O three times to remove DMF. It is then washed with brine, dried (Na₂SO₄), filtered and concentrated *in vacuo* to give the desired amide as a brown solid (2.0 g, quantitative).

10 N.M.R (DMSO-d₆) ¹H δ (ppm) : 3.31 (s, 3H), 4.36 (d, J = 5.9 Hz, 2H), 6.55 (d, J = 8.6 Hz, 1H), 6.59 (s, 2H), 7.15 (m, 2H), 7.35 (m, 4H), 7.80 (d, J = 1.9 Hz, 1H), 8.88 (t, J = 5.9 Hz, 1H);

15 MS (APCI), M/z 411.0 (M + 1).

Step 2 : Methyl 4-(6-Iodo-4-oxo-4H-quinazolin-3-ylmethyl)-benzoate




To a solution of the compound obtained in the preceding Step 1 (2.0 g, 4.84 mmol) in 20 triethyl orthoformate is added catalytic amount of TsOH. The solution is refluxed for 5h, cooled to room temperature. After removal of all volatile solvents *in vacuo*, the residue is purified using flash chromatography to give the desired quinazolinone as a brownish solid. Trituration then afforded the desired compound as a white solid (1.0 g, 50%).

N.M.R (CDCl₃) ¹H δ (ppm) 3.31 (s, 3H), 5.26 (d, 2H), 7.48 (m, 4 H), 7.90 (d, J = 6.8 Hz, 2H), 8.10 (m, 1H), 8.40 (d, J = 1.7 Hz, 1H), 8.60 (d, J = 1.5 Hz, 1H)

MS (APCI), M/z 421.3 (M + 1).


Preparation 5 : 3-(4-Fluoro-benzyl)-6-iodo-3H-pyrido[3,4-d]pyrimidin-4-one

Step 1 : 6-Iodo-1H-pyrido[3,4-d][1,3]oxazine-2,4-dione




- 5 To a suspension of 2-amino-5-iodo-isonicotinic acid (18.0 mmol) in H₂O (20 ml) and concentrated HCl (5 ml) is added dioxane (50 ml) until a clear solution is obtained. Neat diphosgene (5.95 g, 30.0 mmol) is added dropwise (with cooling at times so that the solution does not boil) until a precipitate formed. After stirring at room temperature for 10 minutes, H₂O (100 ml) is added, and the precipitate is filtered and washed with a copious amount of H₂O. The filter cake is dried *in vacuo* to give the desired compound.
- 10


Step 2 : 5-Amino-N-(4-fluoro-benzyl)-2-iodo-isonicotinamide




- To a 50°C solution of a compound obtained in Step 1 (7.27 mmol) in DMF (20 ml) is added 4-fluorobenzylamine (9.45 mmol) dropwise. The reaction is stirred at room temperature for 10 minutes while bubbling is observed (CO₂), and TLC indicates completion of the reaction. The reaction content is poured into a separatory funnel charged with CH₂Cl₂ and H₂O. After separation, the organic layer is washed with H₂O (3x50 ml) and brine (50 ml). The organic layers are then dried (Na₂SO₄), filtered and concentrated *in vacuo*, and the residue optionally is purified using flash chromatography on silica gel to give the desired compound.
- 15
- 20

Step 3 : 3-(4-Fluoro-benzyl)-6-iodo-3H-pyrido[3,4-d]pyrimidin-4-one

To a solution of the compound obtained in Step 2 (7.27 mmol) in triethyl orthoformate is added a catalytic amount of *para*-toluenesulfonic acid. The solution is refluxed for 5 hours, and cooled to room temperature. After removal of all volatiles *in vacuo*, the residue is purified using flash chromatography on silica gel to give the desired compound.

Preparation 6 : Methyl 4-(6-Iodo-4-oxo-4H-pyrido[3,4-d]pyrimidin-3-ylmethyl)-benzoate**Step 1 : Methyl 4-{{(5-Amino-2-iodo-pyridine-4-carbonyl)-amino}-methyl}-benzoate**

To a 50°C solution of the compound obtained in the Step 1 of Preparation 6 (4.84 mmol), in DMF (20 ml) is added the hydrochloride salt of 4-carbomethoxy-benzylamine (1.17 g, 5.8 mmol). The reaction is stirred at room temperature for 1 hour while bubbling is observed (CO₂ evolution), and TLC indicates the completion of the reaction. The reaction content is poured into a separatory funnel charged with CH₂Cl₂ and H₂O. After separation of the layers, the organic layer is washed with H₂O three times to remove DMF. The organic layer is then washed with brine, dried (Na₂SO₄), filtered, and concentrated *in vacuo* to give the desired compound.

Step 2 : Methyl 4-(6-Iodo-4-oxo-4H-pyrido[3,4-d]pyrimidin-3-ylmethyl)-benzoate


To a solution of the compound obtained in Step 1 (4.84 mmol) in triethyl orthoformate is added a catalytic amount of TsOH. The solution is refluxed for 5 hours,

and cooled to room temperature. After removal of all volatile solvents *in vacuo*, the residue is purified using flash chromatography on silica gel to give the desired compound.

Preparation 7 : 3-(4-Fluoro-benzyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid

5


Step 1: Methyl 3-(4-fluoro-benzyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylate



2.0 g (5.27 mmol) of the compound prepared from preparation 3, is dissolved in 50 ml of 1:1 DMF:Methanol, an excess amount of triethylamine, and a catalytic amount of Pd(dppf)Cl₂. The reaction solution is poured into an autoclave and heated at 100°C for 4 hours under carbon monoxide atmosphere. The reaction is cooled to room temperature and filtered. The filtrate is concentrated *in vacuo* and the residue purified on a silica gel column using 1:1 Hex:EtOAc to yield the desired product as a white solid (100%).

15


Step 2: 3-(4-Fluoro-benzyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid



1.7g (5.27 mmol) of the compound obtained in the preceding Step 1 is dissolved in 50 ml of 90% THF:10% Water. 10 equivalents of LiOH is added, and the reaction solution is refluxed for 5 hours. The reaction solution is diluted with 100 ml of water, and concentrated HCl is used to acidify the solution pH to 1.0. The solution is extracted with 200 ml of EtOAc, and the organic layer is washed with 2x100 ml of water and 1x100 ml of brine. The organic layer is dried over MgSO₄ and concentrated to yield 1.5 g of the desired product as an off-white solid.


25

Preparation 8 : 3-(4-Methanesulfonyl-benzyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid



The compound is obtained according to the procedure described in Preparation 7 but using
5 in Step 1 the compound obtained in Preparation 3 in which 4-methanesulfonylbenzylamine is used in place of 4-fluorobenzylamine in the Step 2.

Preparation 9 : 3-[4-(Pyrrolidine-1-sulfonyl)-benzyl]-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid




10

The compound is obtained according to the procedure described in Preparation 7 but using
in step 1 the compound obtained in Preparation 3 in which 4-(pyrrolidine-1-sulfonyl)-benzylamine is used in place of 4-fluorobenzylamine in the Step 2.

15

Preparation 10 : *tert*-butyl 4-(6-*ido*-4-oxo-4H-quinazolin-3-ylmethyl)-benzoate


*Step 1: 2-Amino-5-*ido*-benzamide*



2.0 g (6.90 mmol) of the compound obtained in Step 1 of Preparation 3 is dissolved in
20 approximately 50 ml of DMF, and an excess amount of aqueous ammonium hydroxide is added. After 10 minutes of stirring, the reaction solution is poured into 100 ml of water, and acidified with concentrated HCl, then extracted with 2x100 ml of EtOAc. The combined organic layer is then concentrated to yield 1.8 g (100%) of the desired product as an off-white powder.

N.M.R (DMSO-*d*₆) ¹H δ (ppm) : 6.50 (d, *J* = 8.8Hz, 1H), 6.68 (s, 2H), 7.12 (s, 1H), 7.33 (dd, *J*₁ = 8.8Hz, *J*₂ = 2.1Hz, 1H), 7.77 (d, *J* = 1.9Hz, 2H).

Step 2 : 6-Iodo-3H-quinazolin-4-one




5

1.8 g (6.90 mmol) of compound obtained in the preceding Step 1 is suspended in 30 ml of triethyl orthoformate. A catalytic amount of para-toluene sulfonic acid is added, and the suspension is refluxed for 3 hours. All volatiles are removed *in vacuo*, and the residue is washed with 1:1 dichloromethane:Hexane to yield 1.5 g (80%) of an off white powder as the desired product.

MS(APCI), M/z 270.9 (M-1)

N.M.R (DMSO-*d*₆) ¹H δ (ppm) : 7.42 (d, *J* = 8.5Hz, 1H), 8.09 (dd, *J*₁ = 8.5Hz, *J*₂ = 2.2Hz, 1H), 8.09 (s, 1H), 8.34 (d, *J* = 2.2Hz, 1H), 12.38 (broad s, 1H).

15 **Step 3: tert-Butyl 4-(6-Iodo-4-oxo-4H-quinazolin-3-ylmethyl)-benzoate**




0.9 g (3.31 mmol) of compound obtained in the preceding Step 2 is dissolved in 50 ml of DMF. 1.18 g (3.64 mmol) of cesium carbonate and 0.986 g (3.64 mmol) of ter-butyl 4-bromomethyl-benzoate is added. The reaction is stirred at room temperature for 24 hours. 200 ml of EtOAc is then added, and then washed with 3 x 100 ml of water. The organic layer is dried over MgSO₄ and concentrated. The residue is purified on a silica gel column using 4:1 dichloromethane:hexane increasing gradually to a 1:1 ratio, to yield 0.97 g (62%) of white powder as the desired product.

MS(APCI), M/z 270.9 (M-1)

25 N.M.R (CDCl₃) ¹H δ (ppm) 5.21 (s, 2H), 7.36 (d, *J* = 8.5Hz, 2H), 7.43 (d, *J* = 8.5 Hz, 1H), 7.96 (dd, *J*₁ = 6.6Hz, *J*₂ = 3.1Hz, 2H), 8.01 (dd, *J*₁ = 6.5Hz, *J*₂ = 2.1Hz, 1H), 8.07 (s, 1H), 8.64 (d, *J* = 1.8Hz, 1H)


Example 1 : 3-(4-Methoxy-benzyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid 4-methoxy-benzylamide



5 0.42 g (1.0 mmol) of the compound of Preparation 1 and 2.1 ml (1.85 g, 12.5 mmol) of triethylorthoformate are stirred for 20 hours at 160°C. After cooling, the precipitate obtained are filtered off, and recrystallized from acetonitrile to yield 0.180 g (yield=42%) of the desired compound.

TLC : CH₂Cl₂/MeOH 90/10 R_f = 0.46
 10 N.M.R (DMSO-*d*₆) ¹H δ (ppm) : 3.75 (2s,6H) ; 4.40 (d,2H) ; 5.15 (s,2H) ; 6.85–6.95 (m,4H) ; 7.25 (d,2H) ; 7.35 (d,2H) ; 7.75 (d,1H) ; 8.25 (d,1H) ; 8.65 (s,1H) ; 8.70 (s,1H) ; 9.25 (t,1H)
 IR : 3282, 1661, 1606, 1513, 1248, 1032, 841 cm⁻¹
 MP = 169°C
 15 PURITY : HPLC = 96.7%

Example 2 : 3-(4-Methoxy-benzyl)-2-methyl-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid 4-methoxy-benzylamide, hydrochloride




0.42 g (1.0 mmol) of the compound of Preparation 1, 1 ml of ethanol at 6% of HCl and 103 μl (100 mg, 1 mmol) of acetylacetone are stirred and then heated overnight under reflux. After cooling, the precipitate obtained are filtered off, and recrystallized from acetonitrile to yield the desired compound.

TLC : CH₂Cl₂/MeOH 90/10 R_f = 0.56
 N.M.R (DMSO-*d*₆) ¹H δ (ppm) : 2.70 (s,3H) ; 3.75 (s,6H) ; 4.45 (d,2H) ; 5.35 (s,2H) ; 6.85 –6.95 (m,4H) ; 7.20-7.30 (m,4H) ; 7.30-7.80 (bs,1H) ; 7.80(d,1H) ; 8.35 (d,1H) ; 8.70 (s,1H) ; 9.35 (t,1H).
 IR : 3282, 1702, 1648, 1634, 1547, 1512, 1250, 1178, 1035, 793 cm⁻¹

MP = 208°C

PURITY : HPLC = 98.9%

Example 3 : 3-(4-Methoxy-benzyl)-1-methyl-4-oxo-1,2,3,4-tetrahydro-quinazoline-6-carboxylic acid 4-methoxy-benzylamide




To a stirred solution of 0.42 g (1 mmol) of the compound of Preparation 1 in 2 ml of methanol are added 75 µl (1 mmol) of formaldehyde. The solution obtained is refluxed for 1 hour. Then 820 µl of a solution of NaOH 2M are added, and the reflux is maintained for 20 minutes. After cooling, water is added and the solution extracted with ethyl acetate. The organic layer is decanted, dried and concentrated under vacuum. The crude product (0.32 g 0.75 mmol) is dissolved into 3 ml of anhydrous DMF and stirred under inert atmosphere. 35 mg (0.09 mmol) of NaH are added to this solution and the yellow solution obtained is stirred for 30 minutes at room temperature and then 55 µl (125 mg, 0.9 mmol) of methyl iodide are added. After 30 minutes stirring, the reaction mixture is treated as usual and chromatographed over silica gel (dichloromethane/ether) to give the desired compound.

N.M.R (DMSO-*d*₆) ¹H δ (ppm) : 2.85 (s,3H) ; 3.70 (s,6H) ; 4.40 (d,2H) ; 4.50 (s,2H) ; 4.60 (s,2H) ; 6.80 – 6.95 (m,5H) ; 7.20-7.30 (m,4H) ; 7.95 (d,1H) ; 8.35 (s,1H) ; 8.90 (t,1H)
IR : 1637, 1511, 1467, 1247, 1175 cm⁻¹

MP = 182°C

PURITY : HPLC = 95.6%

Example 4 : 3-(4-Methoxy-benzyl)-1,2,2-trimethyl-4-oxo-1,2,3,4-tetrahydro-quinazoline-6-carboxylic acid 4-methoxy-benzylamide




5 mg of *para*-toluenesulfonic acid are added to a stirred solution of 0.42 g of the compound of preparation 1 in 3 ml of acetone. The reaction mixture is stirred overnight at

room temperature. This process is repeated to obtain a complete reaction. The solution is concentrated under vacuum and the crude product is methylated by addition of methyl iodide in the presence of NaH as described in Example 3. After purification by chromatography, the product obtained is crystallized in a mixture of dichloromethane and ether to give the desired compound.

5 TLC : CH₂Cl₂/Aceton 90/10 Rf = 0.36
 N.M.R (DMSO-d₆) ¹H δ (ppm) : 1.40 (s,6H) ; 2.90 (s,3H) ; 3.75 (s,6H) ; 4.40 (d,2H) ; 4.80 (s,2H) ; 6.80-6.90 (m,4H) ; 6.95 (d,1H) ; 7.20-7.30 (m,4H) ; 7.90 (d,1H) ; 8.40 (s,1H) ; 8.90 (t,1H)
 10 IR : 1638, 1608, 1511, 1499, 1299, 1249, 1174 cm⁻¹
 MP = 168°C
 PURITY : HPLC = 96.4%


Example 5 : 4-[6-(4-Methoxy-benzylcarbamoyl)-4-oxo-1,4-dihydro-2*H*-quinazolin-3-ylmethyl]-benzoic acid



15 The compound is obtained according to the procedure described in the first step of Example 3 using as substrate the compound obtained in the Preparation 2

TLC : CH₂Cl₂/MeOH 90/10 Rf = 0.10
 N.M.R (DMSO-d₆) ¹H δ (ppm) : 3.70 (s,3H) ; 4.35 (d,2H) ; 4.60 (s,2H) ; 4.70 (s,2H) ; 6.75 (d,1H) ; 6.85 (d,2H) ; 7.20-7.30 (m,3H) ; 7.45 (d,2H) ; 7.80 (d,1H) ; 7.90 (d,2H) ; 8.30 (s,1H) ; 8.85 (t,1H) ; 12.85 (bs,1H)
 20 IR : 3314, 1678, 1629, 1513, 1294, 1248 cm⁻¹
 MP = 270°C
 PURITY : HPLC = 97.9%

Example 6 : Methyl 4-[6-(4-Methoxy-benzylcarbamoyl)-1-methyl-4-oxo-1,4-dihydro-2*H*-quinazolin-3-ylmethyl]-benzoate



The compound is obtained according to the procedure described in the second step of

5 Example 3 using as substrate the compound obtained in the Example 5.

TLC : CH₂Cl₂/MeOH 90 /10 R_f = 0.70


N.M.R (DMSO-*d*₆) ¹H δ (ppm) : 2.85 (s,3H) ; 3.70 (s,3H) ; 3.85 (s,3H) ; 4.40 (d,2H) ; 4.55 (s,2H) 4.75 (s,2H) ; 6.80-6.90 (m,3H) ; 7.25 (d,2H) ; 7.45 (d,2H) ; 7.95 (m,3H) ; 8.35 (s,1H) ; 8.90 (t,1H)

10 IR : 3370, 1720, 1651, 1631, 1608, 1514, 1475, 1275, 1246, 1111 cm⁻¹

MP = 175°C

PURITY : HPLC = 94.5%

Example 7 : 4-[6-(4-Methoxy-benzylcarbamoyl)-1-methyl-4-oxo-1,4-dihydro-2*H*-quinazolin-3-ylmethyl]-benzoic acid



The compound is obtained according to the procedure described in the Step 2 of Preparation 5 using as substrate the compound of Example 6.


TLC : CH₂Cl₂/MeOH 90/10 R_f = 0.35

N.M.R (DMSO-*d*₆) ¹H δ (ppm) : 2.85 (s,3H) ; 3.70 (s,3H) ; 4.40 (d,2H) ; 4.55 (s,2H) ; 4.75 (s,2H) ; 6.80-6.90 (m,3H) ; 7.25 (d,2H) ; 7.45 (d,2H) ; 7.95-8.00 (m,3H) ; 8.40 (s,1H) ; 8.90 (t,1H) ; 12.90 (bs,1H)

IR : 3540, 2740, 1709, 1637, 1513, 1476, 1313, 1245, 1173 cm⁻¹


MP = 124°C

PURITY : HPLC = 95.4%

Example 8 : 3-(4-fluorobenzyl)-6-(3-phenyl-prop-1-ynyl)-3 H-quinazolin-4-one

To a THF solution of the compound of Preparation 3 (153 mg, 0.40 mmol) and benzylacetylenylstannane (freshly prepared by addition of *n*-BuLi to the - 78 °C solution of benzylacetylene, followed by quenching with tributyltin chloride) is added catalytic amount of PdCl₂(Ph₃P)₂ and CuI. The resulting suspension is refluxed for 1 hour and cooled to room temperature. After filtration and removal of volatiles *in vacuo*, the residue is purified using flash chromatography to give the desired compound as a white solid (80 mg, 54%).

N.M.R (CDCl₃) ¹H δ (ppm) 3.87 (s,2H), 5.15 (s,2H), 7.15 (t, *J* = 8.3 Hz,1H), 7.26-7.43 (m,5H), 7.62 (d, *J* = 8.3 Hz,1H), 7.77 (dd, *J* = 8.3, 1.9 Hz,1H), 8.08 (s,1H), 8.39 (d, *J* = 1.9 Hz,1H);
MS (APCI), M/z 369.5 (M + 1).


**Example 9 : Methyl 4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-15
-benzoate**

To a THF solution of the compound of Preparation 4 (165 mg, 0.39 mmol) and benzylacetylenylstannane (239 mg, 0.59 mmol, freshly prepared by addition of *n*-BuLi to the - 78°C solution of benzylacetylene, followed by quenching with tributyltin chloride) is added catalytic amount of Pd(PPh₃)₂Cl₂ and CuI. The resulting suspension is refluxed for 1 hour. After filtration and removal of volatiles *in vacuo*, the residue is purified using flash chromatography to give the desired compound as a white solid.

N.M.R (CDCl₃) ¹H δ (ppm) : 3.85 (s,2H), 3.89 (s,3H), 5.23 (s,2H), 7.40 (m,5H), 7.80 (s,1H), 8.00 (d, *J* = 8.3 Hz,2H), 8.40 (s,1H)
MS (APCI), M/z 409.5 (M + 1).


Example 10 : 4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzoic acid

Step 1 : 4-(6-Iodo-4-oxo-4H-quinazolin-3-ylmethyl)-benzoic acid



- 5 To a solution of the compound of Preparation 4 (2.25 g, 5.36 mmol) in 10% H₂O in THF is added LiOH (2.25 g, 53.6 mmol). The reaction is stirred overnight at room temperature. After acidification using concentrated HCl, the reaction mixture is extracted with EtOAc. The organic layer is washed with water and brine, dried (MgSO₄), filtered and concentrated *in vacuo*. The crude product is triturated using a mixture of hexane/EtOAc: 4/1 to yield 2.00g of the desired carboxylic acid as a white powder.
- 10 N.M.R (DMSO-d₆) ¹H δ (ppm) : 5.23 (s,2H), 7.40 (d, J = 8.3 Hz,2H), 7.47 (d, J = 8.6 Hz,1H), 7.87 (d, J = 8.1,2H), 8.1 (dd, J₁ = 8.6 Hz, J₂=1.9Hz,1H) 8.38 (d, J = 1.7 Hz,1H), 8.59 (s,1H), 12.94 (br s,1H)
- MS (APCI), M/z 404.9 (M⁺ 1).

15 **Step 2 : 4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzoic acid**




- 20 To a solution of the compound obtained in Step 1 (0.3 g, 0.739 mmol) in 6.5 ml of DMF, is added diisopropylethylamine (0.381 g, 2.96 mmol), CuI (catalytic amount), 3-phenyl-1-propyne (0.120 g, 1.03 mmol), and Pd(PPh₃)₂Cl₂ (catalytic amount). The reaction mixture is heated to 50°C for 4 hours. The mixture is then diluted with 150 ml of EtOAc, and washed with 3x100 ml of water, 1x100 ml of brine. The organic layer is then dried over MgSO₄, and filtered. The filtrate is concentrated *in vacuo*. The crude product is triturated with a mixture of hexane/ethyl acetate: 8/1 to yield 225 mg of the pure desired product as a light yellow solid.

N.M.R (DMSO-*d*₆) ¹H δ (ppm) : 3.91 (s,2H), 5.23 (s,2H), 7.23-7.43 (m,9H), 7.66 (d, *J*=8.3 Hz,1H), 7.83 (dd, *J*₁=8.6 Hz, *J*₂=1.7 Hz,1H), 7.87 (br s,1H), 8.09 (d, *J*=1.6 Hz,1H), 8.58 (s,1H)


MS (APCI), M/z 395.1 (M⁺ 1).

5 **Example 11: 3-(4-fluorobenzyl)-6-(3-phenyl-prop-1-ynyl)-3H-pyrido[3,4-d]pyrimidin-4-one**



To a THF solution of a compound of Preparation 5 (0.40 mmol) and benzylacetylenyl stannane (freshly prepared by addition of *n*-BuLi to the -78°C solution of benzylacetylene, followed by quenching with tributyltin chloride) is added a catalytic amount of PdCl₂(Ph₃P)₂ and CuI. The resulting suspension is refluxed for 1 hour, and cooled to room temperature. After filtration and removal of volatiles *in vacuo*, the residue is purified using flash chromatography on silica gel to give the desired compound.


15 **Example 12: Methyl 4-[6-(3-phenyl-prop-1-ynyl)-4-oxo-4H-pyrido[3,4-d]pyrimidin-3-ylmethyl]-benzoate**



To a THF solution of the compound of Preparation 6 (0.39 mmol) and benzylacetylenylstannane (239 mg, 0.59 mmol), freshly prepared by addition of *n*-BuLi to the -78°C solution of benzylacetylene, followed by quenching with tributyltin chloride) is added catalytic amount of PdCl₂(Ph₃P)₂ and CuI. The resulting suspension is refluxed for 1 hour. After filtration and removal of volatile *in vacuo*, the residue is purified using flash chromatography to give the desired product.


Example 13 : 4-[6-(3-phenyl-prop-1-ynyl)-4-oxo-4H-pyrido[3,4-d]pyrimidin-3-ylmethyl]-benzoic acid

Step 1: 4-(6-Iodo-4-oxo-4H-pyrido[3,4-d]pyrimidin-3-ylmethyl)-benzoic acid



5 To a solution of the compound of Preparation 6 (5.36 mmol), in 10% H₂O in THF is added LiOH (2.25 g, 53.6 mmol). The reaction is stirred overnight at room temperature. After acidification using concentrated HCl, the reaction mixture is extracted with EtOAc. The organic layer is washed with water and brine, dried (MgSO₄) and filtered *in vacuo*. The crude product is triturated using 4/1 hexane/EtOAc to give the desired compound.


10 **Step 2: 4-[6-(3-phenyl-prop-1-ynyl)-4-oxo-4H-pyrido[3,4-d]pyrimidin-3-ylmethyl]-benzoic acid**



15 To a solution of the compound obtained in Step 1 (0.739 mmol) in 6.5 ml of DMF, is added diisopropylethylamine (0.381 g, 2.96 mmol), CuI (catalytic amount), 3-phenyl-1-propyne (0.120 g, 1.03 mmol), and Pd(PPh₃)₂Cl₂ (catalytic amount). The reaction mixture is warmed to 50 °C for 4 hours. The mixture is then diluted with 150 ml of EtOAc, and washed with 3x100 ml of water, 1x100 ml of brine. The organic layer is then dried over MgSO₄ and filtered. The filtrate is concentrated *in vacuo*. The crude product is triturated with 8/1: hexane/EtOAc to yield the desired compound.

20


Example 14 : 3-(4-Fluoro-benzyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid 3-methoxy-benzylamide



0.2 g (0.671 mmol) of the compound obtained in the Preparation 7 is dissolved in 50 ml of chloroform. 110 mg of 3-methoxybenzyl amine, 205 mg of Mukaiyama reagent and 163 mg of triethylamine is added. The reaction solution is then stirred at room temperature overnight. The reaction solution is concentrated and purified on silica gel column with 1:1 Hexane:EtOAc to yield 150 mg of the desired product as an off white solid.

N.M.R (CDCl_3) ^1H δ (ppm) : 3.79 (s, 3H), 4.62 (d, $J = 5.6\text{Hz}$, 2H), 5.13 (s, 2H), 6.63 (s, 1H), 6.81-7.34 (m, 8 H), 7.75 (d, $J = 8.6\text{Hz}$, 1H), 8.13 (s, 1H), 8.30 (dd, $J_1 = 8.6\text{Hz}$, $J_2 = 2.2\text{Hz}$, 1H), 8.56 (d, $J = 2.0\text{Hz}$, 1H).

10 **Example 15 : 3-(4-Methanesulfonyl-benzyl-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid 4-methoxy-benzylamide**




The compound is obtained according to the procedure described in Example 14 using as substrate the compound obtained in Preparation 8 and 4-methoxybenzylamine.

15 **MS(APCI), M/z 478.1 (M+1)**

N.M.R ($\text{DMSO}-d_6$) ^1H δ (ppm) : 3.18 (s, 3H), 3.72 (s, 3H), 4.39 (d, $J = 5.1\text{Hz}$, 2H), 5.18 (s, 2H), 6.87 (d, $J = 8.3\text{Hz}$, 2H), 7.23 (d, $J = 8.1\text{Hz}$, 2H), 7.25 (s, 1H), 7.56 (d, $J = 8.3\text{Hz}$, 2H), 7.85 (d, $J = 8.1\text{Hz}$, 2H), 8.16 (d, $J = 8.7\text{Hz}$, 1H), 8.51 (s, 1H), 9.15 (s, 1H).

20 **Example 16 : 4-Oxo-3-[4-(pyrrolidine-1-sulfonyl)-benzyl]-3,4-dihydro-quinazoline-6-carboxylic acid 4-methoxy-benzylamide**



The compound is obtained according to the procedure described in Example 14 using as substrate the compound obtained in Preparation 9 and 4-methoxybenzylamine.


25 **MS(APCI), M/z 533.2 (M+1)**

N.M.R ($\text{DMSO}-d_6$) ^1H δ (ppm) : 1.59 (s, 4H), 3.07 (s, 4H), 3.68 (s, 3H), 4.39 (d, $J = 5.5\text{Hz}$, 2H), 5.29 (s, 2H), 6.85 (d, $J = 8.3\text{Hz}$, 2H), 7.23 (d, $J = 8.0\text{Hz}$, 2H), 7.25 (s, 1H), 7.54 (d, J

= 8.1Hz, 2H), 7.74 (d, J = 8.1Hz, 2H), 8.26 (d, J = 8.3Hz, 1H), 8.64 (s, 1H), 8.66 (s, 1H), 9.27 (s, 1H).

Example 17 : 4-[6-(3-Methoxy-benzylcarbamoyl)-4-oxo-4H-quinazolin-3-ylmethyl]-benzoic acid.

5



The desired product is obtained by following the procedure of Example 14, except 4-flurobenzylamine in step 2 of the preparation 3 is replaced by *tert*-butyl 3-aminomethylbenzoate, and at the end stirring the collected residue in an excess amount of trifluoroacetic acid for 30 minutes at room temperature. After removing the volatiles in vacuum, the residue is filtered to furnish the desired product as an off white solid.


N.M.R (DMSO- d_6) 1 H δ (ppm) : 3.71 (s, 3H), 4.43 (d, J = 4.6Hz, 2H), 5.15 (s, 2H), 6.79 (d, J = 7.6Hz, 1H), 6.86 (s, 2H), 7.20-7.26 (m, 2H), 7.40 (d, J = 7.3Hz, 2H), 7.86 (d, J = 7.6Hz, 2H), 8.16 (d, J = 8.1Hz, 1H), 8.53 (s, 1H), 9.20 (s, 1H), 11.80 (s, 1H).

15

Example 18 : 4-[4-oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazoline-3-ylmethyl]-benzoic acid

20

Step 1: *tert*-Butyl 4-[4-oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazoline-3-ylmethyl]-benzoate



25


3.0 g (6.48 mmol) of the compound of Preparation 10 is dissolved in 50 ml of DMF. 3.34 g (25.9 mmol) of diisopropylethylamine, catalytic amount of copper(I) iodide, 3.01 g (25.9 mmol) 3-phenyl-1-propyne and catalytic amount of Pd(PPh₃)₂Cl₂ is then added in that order. The reaction solution is stirred at 50°C for 24 hours, then diluted with 300 ml of EtOAc and washed with 3x200 ml of water, 1x200 ml of brine. The organic layer is dried over MgSO₄ and concentrated. The residue is purified on silica gel column with 4:1

Hexane:EtOAc gradually increasing to 1:1 Hexane:EtOAc to yield a waxy substance as the desired product.

N.M.R (DMSO-*d*₆) ¹H δ (ppm) : 1.50 (s, 9H), 5.24 (s, 2H), 7.42 (d, *J* = 8.8Hz, 2H), 7.49 (d, *J* = 8.6Hz, 1H), 7.84 (d, *J* = 8.6 Hz, 2H), 8.11 (dd, *J*₁ = 8.6 Hz, *J*₂ = 2.2 Hz, 1H), 8.39 (d, *J* = 2.0 Hz, 1H), 8.59 (s, 1H).

5

Step 2: 4-[4-oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazoline-3-ylmethyl]-benzoic acid




An excess amount (20 ml) of trifluoroacetic acid is added to the compound obtained in the preceding Step 1. After 30 minutes of stirring, all volatiles are removed and the residue triturated with 1:1 Hexane:EtOAc. The precipitate is collected via filtration and washed with a small amount of methanol to yield 1.82 g of the desired product as an off-white solid.

N.M.R (DMSO-*d*₆) ¹H δ (ppm) : 3.91 (s, 2H), 5.23 (s, 2H), 7.23-7.43 (m, 9H), 7.66 (d, *J* = 8.3Hz, 1H), 7.83 (dd, *J*₁ = 8.6Hz, *J*₂ = 1.7Hz, 1H), 7.87 (broad s, 1H), 8.09 (d, *J* = 1.6Hz, 1H), 8.58 (s, 1H).

10
15

Example 19 : 4-{6-[3-(4-Methoxy-phenyl)-prop-1-ynyl]-4-oxo-4H-quinazoline-3-ylmethyl}-benzoic acid




20

The product is obtained by following the procedure of Example 18, the only difference is that 3-phenyl-1-propyne used in Step 1 is replaced by 1-methoxy-4-prop-2-ynyl-benzene. The product is obtained as a white solid.

N.M.R (DMSO-*d*₆) ¹H δ (ppm) : 3.70 (s, 3H), 3.83 (s, 2H), 5.24 (s, 2H), 6.89 (d, *J* = 8.5Hz, 2H), 7.29 (d, *J* = 8.3Hz, 2H), 7.41(d, *J* = 8.0Hz, 2H), 7.65 (d, *J* = 8.3Hz, 1H), 7.81 (dd, *J*₁ = 8.3Hz, *J*₂ = 1.5Hz, 1H), 7.88 (d, *J* = 8.1Hz, 2H), 8.08 (d, *J* = 1.5Hz, 1H), 8.58 (s, 1H), 12.94 (broad s, 1H).

25

Example 20 : 4-[4-oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazoline-3-ylmethyl]-benzamide




5 0.1 g (0.254 mmol) of the compound of Example 18 is suspended in 50 ml of dichloromethane. 35.4 mg of oxalyl chloride (0.279 mmol) is added, followed by 1 drop of DMF. The reaction is refluxed under nitrogen for 2 hours, and stirred at room temperature for an additional 12 hours. Then an excess amount of 0.5 M ammonia in dioxane is added. The reaction is stirred at room temperature for 1 hour. The solvent is then removed in 10 vacuum and the residue is washed with 1:1 water:methanol to yield 70 mg of an off-white powder as the desired product.

MS(APCI), M/z 394.1 (M^+1).

N.M.R (DMSO- d_6) 1H δ (ppm) : 3.92 (s, 2H), 5.21 (s, 2H), 7.24-7.39 (m, 9H), 7.66 (d, J = 8.5 Hz, 1H), 7.80-7.92 (m, 4H), 8.10 (s, 2H), 8.58 (s, 1H).

15

Example 21 : 3-(4-Fluoro-benzyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide




Compound of the Preparation 7 (227 mg, 0.76 mmol), 2-methoxy-pyridin-4-ylmethylamine (138 mg, 1.0 mmol) and the Mukaiyama reagent (256 mg, 1.0 mmol) are dissolved in CHCl₃ (10 ml), Et₃N (1 ml, excess) is added. The resulting solution is refluxed for 3 h, cooled to room temperature. The solution is then purified via a flash chromatography to give the desired product as a white solid, 34 mg, 63% yield.

MS (APCI), M/z 419.2 ($M + 1$).

25 N.M.R (DMSO- d_6) 1H δ (ppm) : 9.40 (t, J = 5.9 Hz, 1H), 8.70 (s, 1H), 8.69 (s, 1H), 8.28 (dd, 1H), 8.07 (d, J = 5.4 Hz, 1H), 7.77 (d, J = 8.3 Hz, 1H), 7.44 (m, 1H), 7.19 (t, J = 8.7

Hz, 1H), 6.91 (d, J = 5.1 Hz, 1H), 6.69 (s, 1H), 5.19 (s, 2H), 4.45 (d, J = 5.9 Hz, 1H), 3.80 (s, 3H)

**Example 22 : 3-[(3,5-difluoro-4-hydroxy)-benzyl]-6-(3-phenyl-prop-1-ynyl)-3H-
5 quinazolin-4-one**




To a solution of 3-[(3,5-difluoro-4-hydroxy)-benzyl]-6-iodo-3H-quinazolin-4-one (obtained following the procedure of preparation 3 but using in step 2 (3,5-difluoro-4-hydroxy)-benzylamine) (0.3 g, 720 mmol) in 6.5 ml of DMF, is added diisopropylethyl amine (0.381 g, 2.96 mmol), 3-phenyl-1-propyne (0.34 g, 2.9 mmol), CuI (catalytic amount), and Pd(PPh₃)₂Cl₂ (catalytic amount). The reaction mixture is heated to 50°C for 4 hours. The mixture is then diluted with 150 ml of EtOAc, and washed with 3x100 ml of water, 1x100 ml of brine. The organic layer is then dried over MgSO₄ and filtered. The filtrate is concentrated *in vacuo*. The crude product is purified via a flash chromatography to yield 225 mg of the pure desired product as a light yellow solid.

MS (APCI), M/z 403.1 (M + 1).

N.M.R (DMSO-*d*₆) ¹H δ (ppm) : 8.46 (s, 1H), 8.25 (d, J = 2.0 Hz, 1H), 7.1-7.8 (m, 9H), 5.20 (s, 2H), 3.91 (s, 2H)

20 Example 23 : 3-(3-Fluoro-benzyl)-4-oxo-3,4-dihydro-pyrido[3,4-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide

Step 1: 6-Chloro-3-(3-fluoro-benzyl)-3H-pyrido[3,4-d]pyrimidin-4-one




The starting material, 6-chloro-3H-pyrido[3,4-d]pyrimidin-4-one (710 mg, 3.92 mmol, prepared according to *J. Chem. Soc., Perkin Trans.* 1996, 1, 2221) is dissolved in DMF (20 ml). Cs₂CO₃ (1.66 g, 5.1 mmol) and 3-fluorobenzylchloride (737 mg, 5.1 mmol) are added

subsequently. The reaction is stirred at room temperature overnight, poured into water. After extraction with CH₂Cl₂, the organic layer is washed with H₂O and brine, dried (Na₂SO₄) and filtered. After removal of the solvents, the residue is purified via a flash chromatography to give the product as a white solid.

5 MS (APCI), M/z 290.0 (M + 1).

N.M.R (CDCl₃) ¹H δ (ppm) 8.92 (s, 1H), 8.10 (d, J = 9.6 Hz, 2H), 7.0-7.4 (m, 5H), 5.17 (m, 2H).

10 Step 2: Methyl 3-(3-fluorobenzyl)-4-oxo-3,4-dihydro-pyrido[3,4-d]pyrimidine-6-carboxylate




The compound obtained in the preceding Step 1 (3.0 g, 1.07 mmol), is dissolved in 50 ml of methanol, with an excess amount of triethylamine, and a catalytic amount of Pd(dppf)Cl₂. The reaction solution is poured into an autoclave and heated at 100°C for 4 hours under the carbon monoxide atmosphere. The reaction is cooled to room temperature and filtered. The filtrate is concentrated in vacuum and the residue is purified on a silica gel column using 1:1 Hex:EtOAc to yield the desired product as a white solid (100%).

15 MS (APCI), M/z 314.0 (M + 1).

N.M.R (CDCl₃) ¹H δ (ppm): 9.24 (s, 1H), 8.95 (s, 1H), 8.28 (s, 1H), 7.0-7.4 (m, 4H), 5.24 (s, 2H), 4.08 (s, 3H)

Step 3: 3-(3-Fluoro-benzyl)-4-oxo-3,4-dihydro-pyrido[3,4-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide




25 To a 0°C solution of 3-methoxybenzylamine (144 mg, 1.05 mmol) in CH₂Cl₂ is added AlMe₃ (0.52 ml, 1.05 mmol). The reaction is stirred at room temperature for 2 h. Then a solution of the compound obtained in the preceding Step 2 (111 mg, 0.35 mmol) in CH₂Cl₂ is added and the resulting reaction is stirred at room temperature for 2 h, and poured into

water. After extraction with CH_2Cl_2 , the organic layer is washed with H_2O and brine, dried (Na_2SO_4) and filtered. After removal of the solvents, the residue is purified via a flash chromatography to give the product as a white solid.

MS (APCI), M/z 419.1 (M + 1).

5 N.M.R (CDCl_3) ^1H δ (ppm) : 9.40 (t, 1H), 9.09 (s, 1H), 8.76 (s, 1H), 8.54 (s, 1H), 6.7-7.4 (m, 11H), 5.22 (s, 2H), 4.45 (d, $J = 6.6$ Hz, 1H), 3.67 (s, 3H)

Example 24 : 3-(3-Fluoro-benzyl)-4-oxo-3,4-dihydro-pyrido[3,4-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide




10

The compound is obtained according to the procedure of Example 23 using in the Step 3, 4-methoxybenzylamine.

MS (APCI), M/z 419.1 (M + 1).

N.M.R (CDCl_3) ^1H δ (ppm) : 9.40 (t, 1H), 9.09 (s, 1H), 8.76 (s, 1H), 8.54 (s, 1H), 7.0-7.4 (m, 9H), 6.80 (d, $J = 1.6$ Hz, 2H), 5.22 (s, 2H), 4.45 (d, $J = 6.6$ Hz, 1H), 3.67 (s, 3H)

Example 25 : 4-[4-Oxo-6-(3-phenyl-propa-1,2-dienyl)-4H-quinazolin-3-ylmethyl]-benzoic acid



20 0.105 g (0.257 mmol) of the compound of Example 9 is dissolved in 25 ml of 90% THF:10% water. 10 equivalents of LiOH are added. The reaction is refluxed for 3 hours, 200 ml of EtOAc are added, acidified by concentrated HCl and the solution is washed with 2x100 ml of water and 1x100 ml of brine. Organic layer dried over MgSO_4 , and concentrated. The residue is purified on a silica gel column with 95% EtOAc:5% MeOH to yield 30 mg of the product as a light yellow powder.

25 MS(APCI), M/z 481.2 (M+1)

N.M.R (DMSO-*d*₆) ¹H δ (ppm) : 5.23 (s, 2H). 6.90 (d, *J* = 6.6Hz, 1H), 7.02(d, *J* = 6.6Hz, 1H), 7.24 (m, 1H), 7.33 (d, *J* = 4.1, 4H), 7.40 (d, *J* = 8.3Hz, 2H), 7.65(d, *J* = 8.3Hz, 1H), 7.75 (dd, *J*₁ = 8.5Hz, *J*₂ = 1.7Hz, 1H), 7.87 (d, *J*= 8.1Hz, 2H), 8.07 (s, 1H), 8.53(s, 1H).

Examples 26 to 71 :

These compounds are obtained according to the procedure described in the Preparation 5 and Example 8 using the corresponding substrates and reagents.

- 26. 4-{6-[3-(4-Methoxy-phenyl)-prop-1-ynyl]-4-oxo-4*H*-quinazolin-3-ylmethyl}-benzoic acid,
- 27. 3-(4-Methanesulfonyl-benzyl)-6-[3-(4-methoxy-phenyl)-prop-1-ynyl]-3*H*-quinazolin-4-one,
- 28. 4-{6-[3-(3-Methoxy-phenyl)-prop-1-ynyl]-4-oxo-4*H*-quinazolin-3-ylmethyl}-benzoic acid,
- 29. 3-(4-Methanesulfonyl-benzyl)-6-[3-(3-methoxy-phenyl)-prop-1-ynyl]-3*H*-quinazolin-4-one,
- 30. 4-[4-oxo-6-(3-pyridin-4-yl-prop-1-ynyl)-4*H*-quinazolin-3-ylmethyl]-benzoic acid,
- 31. 3-(4-Methanesulfonyl-benzyl)-6-(3-pyridin-4-yl-prop-1-ynyl)-3*H*-quinazolin-4-one
- 32. 4-[4-oxo-6-(3-pyridin-3-yl-prop-1-ynyl)-4*H*-quinazolin-3-ylmethyl]-benzoic acid,
- 33. 3-(4-Methanesulfonyl-benzyl)-6-(3-pyridin-3-yl-prop-1-ynyl)-3*H*-quinazolin-4-one,
- 34. 4-{6-[3-(4-fluro-phenyl)-prop-1-ynyl]-4-oxo-4*H*-quinazolin-3-ylmethyl}-benzoic acid,
- 35. 6-[3-(4-Fluro-phenyl)-prop-1-ynyl]-3-(4-methanesulfonyl-benzyl)-3*H*-quinazolin-4-one,
- 36. 4-{6-[3-(3-fluro-phenyl)-prop-1-ynyl]-4-oxo-4*H*-quinazolin-3-ylmethyl}-benzoic acid,
- 37. 6-[3-(3-Fluro-phenyl)-prop-1-ynyl]-3-(4-methanesulfonyl-benzyl)-3*H*-quinazolin-4-one,

38. 4-{6-[3-(4-chloro-phenyl)-prop-1-ynyl]-4-oxo-4*H*-quinazolin-3-ylmethyl}-benzoic acid,
39. 6-[3-(4-Chloro-phenyl)-prop-1-ynyl]-3-(4-methanesulfonyl-benzyl)-3*H*-quinazolin-4-one,
- 5 40. 4-{6-[3-(3-chloro-phenyl)-prop-1-ynyl]-4-oxo-4*H*-quinazolin-3-ylmethyl}-benzoic acid,
41. 6-[3-(3-Chloro-phenyl)-prop-1-ynyl]-3-(4-methanesulfonyl-benzyl)-3*H*-quinazolin-4-one,
42. 4-{6-[3-(4-bromo-phenyl)-prop-1-ynyl]-4-oxo-4*H*-quinazolin-3-ylmethyl}-benzoic acid,
- 10 43. 6-[3-(4-bromo-phenyl)-prop-1-ynyl]-3-(4-methanesulfonyl-benzyl)-3*H*-quinazolin-4-one,
44. 4-{6-[3-(3-bromo-phenyl)-prop-1-ynyl]-4-oxo-4*H*-quinazolin-3-ylmethyl}-benzoic acid,
- 15 45. 6-[3-(3-bromo-phenyl)-prop-1-ynyl]-3-(4-methanesulfonyl-benzyl)-3*H*-quinazolin-4-one,
46. 4-{6-[3-(4-nitro-phenyl)-prop-1-ynyl]-4-oxo-4*H*-quinazolin-3-ylmethyl}-benzoic acid,
47. 3-(4-Methanesulfonyl-benzyl)-6-[3-(4-nitro-phenyl)-prop-1-ynyl]-3*H*-quinazolin-4-one,
- 20 48. 4-{6-[3-(2-methoxy-pyridin-4-yl)-prop-1-ynyl]-4-oxo-4*H*-quinazolin-3-ylmethyl}-benzoic acid,
49. 3-(4-Methanesulfonyl-benzyl)-6-[3-(2-methoxy-pyridin-4-yl)-prop-1-ynyl]-3*H*-quinazolin-4-one,
- 25 50. 4-{6-[3-(4-methylsulfanyl-phenyl)-prop-1-ynyl]-4-oxo-4*H*-quinazolin-3-ylmethyl}-benzoic acid.
51. 3-(4-Methanesulfonyl-benzyl)-6-[3-(4-methylsulfanyl-phenyl)-prop-1-ynyl]-3*H*-quinazolin-4-one
52. 4-{6-[3-(3-methylsulfanyl-phenyl)-prop-1-ynyl]-4-oxo-4*H*-quinazolin-3-ylmethyl}-benzoic acid
- 30 53. 3-(4-Methanesulfonyl-benzyl)-6-[3-(3-methylsulfanyl-phenyl)-prop-1-ynyl]-3*H*-quinazolin-4-one

54. 4-[4-oxo-6-(3-p-tolyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzoic acid
55. 3-(4-Methanesulfonyl-benzyl)-6-(3-p-tolyl-prop-1-ynyl)-3H-quinazolin-4-one
56. 4-[4-oxo-6-(3-m-tolyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzoic acid
57. 3-(4-Methanesulfonyl-benzyl)-6-(3-m-tolyl-prop-1-ynyl)-3H-quinazolin-4-one
58. 4-[6-(3-Imidazol-1-yl-prop-1-ynyl)-4-oxo-4H-quinazolin-3-ylmethyl]-benzoic acid
59. 4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzenesulfonamide
60. 4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzonitrile
- 10 61. 3-(3-Chloro-benzyl)-6-(4-phenyl-but-1-ynyl)-3H-quinazolin-4-one
62. 3-(3-Chloro-benzyl)-6-(3-phenyl-prop-1-ynyl)-3H-quinazolin-4-one
63. 4-[4-Oxo-6-(3-pyrazol-1-yl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzoic acid
64. 6-(3-Phenyl-prop-1-ynyl)-3-[4-(1H-tetrazol-5-yl)-benzyl]-3H-quinazolin-4-one
- 15 65. 3-(3,4-Difluoro-benzyl)-6-[3-(pyridin-4-yloxy)-prop-1-ynyl]-3H-quinazolin-4-one
66. 3-(3,4-Difluoro-benzyl)-6-[3-(4-methoxy-phenyl)-prop-1-ynyl]-3H-quinazolin-4-one
67. N-{4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-phenyl}-acetamide
- 20 68. 3-(3,4-Difluoro-benzyl)-6-(3-phenyl-prop-1-ynyl)-3H-quinazolin-4-one
69. 3-(4-Acetyl-benzyl)-6-[3-(4-methoxy-phenyl)-prop-1-ynyl]-3H-quinazolin-4-one
70. 6-(3-Phenyl-prop-1-ynyl)-3-pyridin-4-ylmethyl-3H-quinazolin-4-one
71. 6-[3-(4-Methoxy-phenyl)-prop-1-ynyl]-3-pyridin-4-ylmethyl-3H-quinazolin-4-one
- 25

Examples 72 to 103 :

These compounds are obtained according to the procedure described in the Preparation 6 and Example 11 using the corresponding substrates and reagents.

- 30 72. 4-{6-[3-(4-methoxy-phenyl)-prop-1-ynyl]-4-oxo-4H-pyrido[3,4-d]pyrimidin-3-ylmethyl}-benzoic acid,

73. 3-(4-methanesulfonyl-benzyl)-6-[3-(4-methoxyl-phenyl)-prop-1-ynyl]-3*H*-pyrido[3,4-*d*]pyrimidin-4-one,
74. 4-{6-[3-(3-methoxy-phenyl)-prop-1-ynyl]-4-oxo-4*H*-pyrido[3,4-*d*]pyrimidin-3-ylmethyl}-benzoic acid,
- 5 75. 3-(4-Methanesulfonyl-benzyl)-6-[3-(3-methoxyl-phenyl)-prop-1-ynyl]-3*H*-pyrido[3,4-*d*]pyrimidin-4-one,
76. 4-[4-oxo-6-(3-pyridin-4-yl-prop-1-ynyl)-4*H*-pyrido[3,4-*d*]pyrimidin-3-ylmethyl]-benzoic acid,
77. 3-(4-Methanesulfonyl-benzyl)-6-(3-pyridin-4-yl-prop-1-ynyl)-3*H*-pyrido[3,4-*d*]pyrimidin-4-one,
- 10 78. 4-[4-oxo-6-(3-pyridin-3-yl-prop-1-ynyl)-4*H*-pyrido[3,4-*d*]pyrimidin-3-ylmethyl]-benzoic acid,
79. 3-(4-Methanesulfonyl-benzyl)-6-(3-pyridin-3-yl-prop-1-ynyl)-3*H*-pyrido[3,4-*d*]pyrimidin-4-one,
- 15 80. 4-{6-[3-(4-fluro-phenyl)-prop-1-ynyl]-4-oxo-4*H*-pyrido[3,4-*d*]pyrimidin-3-ylmethyl}-benzoic acid,
81. 6-[3-(4-Fluro-phenyl)-prop-1-ynyl]-3-(4-methanesulfonyl-benzyl)-3*H*-pyrido[3,4-*d*]pyrimidin-4-one,
82. 4-{6-[3-(3-fluro-phenyl)-prop-1-ynyl]-4-oxo-4*H*-pyrido[3,4-*d*]pyrimidin-3-ylmethyl}-benzoic acid,
- 20 83. 6-[3-(3-Fluro-phenyl)-prop-1-ynyl]-3-(4-methanesulfonyl-benzyl)-3*H*-pyrido[3,4-*d*]pyrimidin-4-one,
84. 4-{6-[3-(4-chloro-phenyl)-prop-1-ynyl]-4-oxo-4*H*-pyrido[3,4-*d*]pyrimidin-3-ylmethyl}-benzoic acid,
- 25 85. 6-[3-(4-Chloro-phenyl)-prop-1-ynyl]-3-(4-methanesulfonyl-benzyl)-3*H*-pyrido[3,4-*d*]pyrimidin-4-one,
86. 4-{6-[3-(3-chloro-phenyl)-prop-1-ynyl]-4-oxo-4*H*-pyrido[3,4-*d*]pyrimidin-3-ylmethyl}-benzoic acid,
87. 6-[3-(3-Chloro-phenyl)-prop-1-ynyl]-3-(4-methanesulfonyl-benzyl)-3*H*-pyrido[3,4-*d*]pyrimidin-4-one,
- 30 88. 4-{6-[3-(4-bromo-phenyl)-prop-1-ynyl]-4-oxo-4*H*-pyrido[3,4-*d*]pyrimidin-3-ylmethyl}-benzoic acid,

89. 6-[3-(4-Bromo-phenyl)-prop-1-ynyl]-3-(4-methanesulfonyl-benzyl)-3*H*-pyrido[3,4-*d*]pyrimidin-4-one,
90. 4-{6-[3-(3-bromo-phenyl)-prop-1-ynyl]-4-oxo-4*H*-pyrido[3,4-*d*]pyrimidin-3-ylmethyl}-benzoic acid,
5 91. 6-[3-(3-Bromo-phenyl)-prop-1-ynyl]-3-(4-methanesulfonyl-benzyl)-3*H*-pyrido[3,4-*d*]pyrimidin-4-one,
92. 4-{6-[3-(4-nitro-phenyl)-prop-1-ynyl]-4-oxo-4*H*-pyrido[3,4-*d*]pyrimidin-3-ylmethyl}-benzoic acid,
10 93. 3-(4-Methanesulfonyl-benzyl)-6-[3-(4-nitro-phenyl)-prop-1-ynyl]-3*H*-pyrido[3,4-*d*]pyrimidin-4-one,
94. 4-{6-[3-(2-methoxy-pyridin-4-yl)-prop-1-ynyl]-4-oxo-4*H*-pyrido[3,4-*d*]pyrimidin-3-ylmethyl}-benzoic acid,
95. 3-(4-Methanesulfonyl-benzyl)-6-[3-(2-methoxy-pyridin-4-yl)-prop-1-ynyl]-3*H*-pyrido[3,4-*d*]pyrimidin-4-one,
15 96. 4-{6-[3-(4-methylsulfanyl-phenyl)-prop-1-ynyl]-4-oxo-4*H*-pyrido[3,4-*d*]pyrimidin-3-ylmethyl}-benzoic acid,
97. 3-(4-Methanesulfonyl-benzyl)-6-[3-(4-methylsulfanyl-phenyl)-prop-1-ynyl]-3*H*-pyrido[3,4-*d*]pyrimidin-4-one,
98. 4-{6-[3-(3-methylsulfanyl-phenyl)-prop-1-ynyl]-4-oxo-4*H*-pyrido[3,4-*d*]pyrimidin-3-ylmethyl}-benzoic acid,
20 99. 3-(4-Methanesulfonyl-benzyl)-6-[3-(3-methylsulfanyl-phenyl)-prop-1-ynyl]-3*H*-pyrido[3,4-*d*]pyrimidin-4-one,
100. 4-[4-oxo-6-(3-*p*-tolyl-prop-1-ynyl)-4*H*-pyrido[3,4-*d*]pyrimidin-3-ylmethyl]-benzoic acid,
25 101. 3-(4-Methanesulfonyl-benzyl)-6-(3-*p*-tolyl-prop-1-ynyl)-3*H*-pyrido[3,4-*d*]pyrimidin-4-one,
102. 4-[4-oxo-6-(3-*m*-tolyl-prop-1-ynyl)-4*H*-pyrido[3,4-*d*]pyrimidin-3-ylmethyl]-benzoic acid,
103. and 3-(4-Methanesulfonyl-benzyl)-6-(3-*m*-tolyl-prop-1-ynyl)-3*H*-pyrido[3,4-*d*]pyrimidin-4-one.
30

Examples 104 and 105

These compounds are obtained according to the procedure described in Examples 14 and 21 using the corresponding substrates and reagents.

104. 3-(3,4-Difluoro-benzyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide

5 105. 3-(3,4-Difluoro-benzyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid 4-methoxy-benzylamide

PHARMACOLOGICAL STUDIES OF COMPOUNDS OF THE INVENTION

Example 106 : Evaluation of the in vitro activity of the MMP-13 inhibitor compounds according to the invention.

10 The inhibitory activity of the compounds of formula (I) according to the invention with respect to matrix metalloprotease-13 is evaluated by testing the ability of the compounds of the invention to inhibit the proteolysis of a peptide substrate with MMP-13.

The peptide substrate used in the test is the following peptide: Ac-Pro-Leu-Gly-thioester-Leu-Leu-Gly-OEt.

15 The inhibitory activity of a compound of formula (I) according to the invention is expressed as the IC₅₀ value, which is the concentration of inhibitor for which an inhibition of 50% of the activity of the matrix metalloprotease under consideration is observed.

To carry out this test, a reaction medium of 100 µl volume is prepared, containing: 50 mM of HEPES buffer, 10 mM of CaCl₂ and 1 mM of 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB), and 100 µM of substrate, the pH being adjusted to 7.0.

20 Increasing concentrations of the inhibitory compound present in a 2.0% DMSO solution and 2.5 nM of the catalytic domain of human MMP-13 are added to the test samples.

The concentrations of inhibitors present in the test samples range from 100 µM to 0.5 nM.

25 The measurement of the proteolysis of the substrate peptide is monitored by measuring the absorbence at 405 nm using a spectrophotometer for reading microplates, at the laboratory temperature, the measurements being carried out continuously for 10 to 15 minutes.

The IC₅₀ values are calculated from a curve in which the percentage of the catalytic activity relative to the control is represented on the X-axis and the concentration of inhibitor is represented on the Y-axis.


The IC₅₀ values on MMP-13 of the compounds of Examples 1 to 10, 14-19, 21, 23-25, 58-60, 62, 64-71, 104, 105 are all below 1 µM.

The test described above for the inhibition of MMP-13 was also adapted and used to determine the ability of the compounds of formula (I) to inhibit the matrix metalloproteases MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-12 and MMP-14.

5 The results obtained show that the compounds according to the invention generally have IC₅₀ values for MMP-13 which are about 100 times lower than the IC₅₀ values for the same compounds with respect to the other matrix metalloproteases tested.

CLAIMS


1- A compound selected from those of formula (I):



wherein:

- 5 • X_1 , X_2 , and X_3 , independently of each other, represent a nitrogen atom or a group $-CR_3$ in which R_3 represents a group selected from hydrogen, (C_1-C_6) alkyl, amino, mono(C_1-C_6)alkylamino, di(C_1-C_6)alkylamino, hydroxy, (C_1-C_6)alkoxy, and halogen, with the proviso that not more than two of the groups X_1 , X_2 and X_3 simultaneously represent a nitrogen atom,

10 • G_1 represents a group selected from those of formulae (i/a) and (i/b):



in which:

- 15

 - the carbon atom with number 2 is attached to the group N-R₁ in the ring,
 - R₄ and R₅, identical or different, independently of each other, represent a group selected from hydrogen, (C₁-C₆)alkyl, aryl, aryl(C₁-C₆)alkyl, cycloalkyl, cycloalkyl(C₁-C₆)alkyl, heteroaryl, heteroaryl(C₁-C₆)alkyl, heterocycloalkyl, and heterocycloalkyl(C₁-C₆)alkyl,
 - R₆ represents a group selected from :
 - ✓ hydrogen, trifluoromethyl, OR₇, NR₇R₈, in which R₇ and R₈, identical or different independently of each other, represent hydrogen or (C₁-C₆)alkyl,
 - ✓ (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, aryl, aryl(C₁-C₆)alkyl, cycloalkyl(C₁-C₆)alkyl, heteroaryl, heteroaryl(C₁-C₆)alkyl, heterocycloalkyl, and heterocycloalkyl(C₁-C₆)alkyl, these groups being optionally substituted by one or

20

more groups, which may be identical or different independently of each other, selected from halogen, amino, mono(C₁-C₆)alkylamino, di(C₁-C₆)alkylamino, each alkyl moiety being identical or different independently of each other, cyano, trihalogeno(C₁-C₆)alkyl, (C₁-C₆)acyl, -C(=O)OR₇, -OR₇ and -SR₇, in which R₇ is as defined hereinbefore,

5

- G₂ represents a group selected from carbon-carbon triple bond, -CH=C=CH-, C=O, C=S, S(O)_{n1} in which n1 represents an integer from 0 to 2 inclusive, and a group of formula (i/c):




10 in which the carbon atom with number 1 is attached to the bicycle of the compound of formula (I), Y₁ represents a group selected from oxygen, sulphur, -NH and -N(C₁-C₆)alkyl, and Y₂ represents a group selected from oxygen, sulphur, -NH and -N(C₁-C₆)alkyl,

- n represents an integer from 0 to 6 inclusive,
- Z₁ represents -CR₉R₁₀, wherein R₉ and R₁₀, identical or different independently of each other, represent a group selected from hydrogen, (C₁-C₆)alkyl, trihalogeno(C₁-C₆)alkyl, halogen, -OR₇, -SR₇, and -C(=O)OR₇, in which R₇ is as defined hereinbefore, amino, mono(C₁-C₆)alkylamino, di(C₁-C₆)alkylamino in which each alkyl moiety is identical or different independently of each other, and
 - wherein when n is greater than or equal to 2, the hydrocarbon chain Z₁ optionally contains one to two isolated or conjugated multiple bonds,
 - and/or wherein when n is greater than or equal to 2, one of said -CR₉R₁₀ may optionally be replaced with a group selected from oxygen, S(O)_{n1} in which n1 is as defined hereinbefore, -NH and -N(C₁-C₆)alkyl,
- A represents a group selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, these groups being 5- or 6-membered monocycle or bicyclic composed of two 5- or 6-membered monocycle,

25

- R₁ represents a group selected from :
 - hydrogen,
 - (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, these groups may be optionally substituted with one or more groups, which may be identical or different independently of each other, selected from amino, cyano, trihalogeno(C₁-C₆)alkyl, cycloalkyl, -C(=O)NR₇R₈, -C(=O)OR₈, OR₈, SR₈, in which R₇ and R₈, which may be identical or different independently of each other, represent hydrogen or (C₁-C₆)alkyl,
 - and the group of formula (i/d) :



- ✓ in which p is an integer from 0 to 8 inclusive,
- ✓ Z₂ represents -CR₁₁R₁₂ wherein R₁₁ and R₁₂, identical or different independently of each other, represent a group selected from hydrogen, (C₁-C₆)alkyl, phenyl, trihalogeno(C₁-C₆)alkyl, halogen, amino, OR₇, SR₇ and -C(=O)OR₇ in which R₇ represents hydrogen or (C₁-C₆)alkyl, and
- wherein when p is greater than or equal to 2, the hydrocarbon chain Z₂ optionally contains one or two isolated or conjugated multiple bonds,
- and/or wherein n is greater than or equal to 2, one of said -CR₁₁R₁₂ may optionally be replaced with a group selected from oxygen, S(O)_{n1} in which n1 is as defined hereinbefore, -NH, -N(C₁-C₆)alkyl, and carbonyl,
- ✓ B represents a group selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, these groups being 5- or 6-membered monocycle or bicyclic composed of two 5- or 6- membered monocycle,
- ✓ q is an integer from 0 to 7 inclusive,

✓ the group(s) G₃, which may be identical or different independently of each other, is (are) selected from (C₁-C₆)alkyl, halogen, CN, NO₂, CF₃, OCF₃, -(CH₂)_kNR₁₃R₁₄, -N(R₁₃)C(=O)R₁₄, -N(R₁₃)C(=O)OR₁₄, -N(R₁₃)SO₂R₁₄, -N(SO₂R₁₃)₂, -OR₁₃, -S(O)_{k1}R₁₃, -SO₂-N(R₁₃)-(CH₂)_{k2}-NR₁₄R₁₅, -(CH₂)_kSO₂NR₁₃R₁₄, -X₄(CH₂)_kC(=O)OR₁₃, -(CH₂)_kC(=O)OR₁₃, -C(=O)O-(CH₂)_{k2}-NR₁₃R₁₄, -C(=O)O-(CH₂)_{k2}-C(=O)OR₁₆, -X₄(CH₂)_kC(=O)NR₁₃R₁₄, -(CH₂)_kC(=O)NR₁₃R₁₄, -R₁₇-C(=O)OR₁₃, -X₅-R₁₈, and -C(=O)-R₁₉-NR₁₃R₁₄ in which :

5 - X₄ represents a group selected from oxygen atom, sulphur atom optionally substituted by one or two oxygen atoms, and nitrogen atom substituted by a hydrogen atom or a (C₁-C₆)alkyl group,

10 - k is an integer from 0 to 3 inclusive,

- k1 is an integer from 0 to 2 inclusive,

- k2 is an integer from 1 to 4 inclusive,

15 - R₁₃, R₁₄ and R₁₅, which may be identical or different independently of each other, are selected from hydrogen and (C₁-C₆)alkyl,

- R₁₆ represents a group selected from (C₁-C₆)alkyl, -R₁₉-NR₁₃R₁₄, -R₁₉-NR₁₃-C(=O)-R₁₉-NR₁₄R₁₅, and -C(=O)O-R₁₉-NR₁₃R₁₄ in which R₁₉ represents a linear or branched (C₁-C₆)alkylene group, and R₁₃, R₁₄ and R₁₅ are as defined hereinbefore,

20 - R₁₇ represents a (C₃-C₆)cycloalkyl group,

- X₅ represents a group selected from single bond, -CH₂-, oxygen atom, sulphur atom optionally substituted by one or two oxygen atoms, and nitrogen atom substituted by hydrogen atom or (C₁-C₆)alkyl group,

- R₁₈ represents a group selected from :

- o 5- or 6-membered monocycle aryl, heteroaryl, which is optionally substituted by one or more groups, which may be identical or different, selected from (C₁-C₆)alkyl, halogen, hydroxy, cyano, tetrazolyl, amino, and -C(=O)OR₇ wherein R₇ represents hydrogen or (C₁-C₆)alkyl,
 - 5 o and 5- or 6-membered monocycle cycloalkyl, heterocycloalkyl, which is optionally substituted by one or more groups, which may be identical or different, selected from (C₁-C₆)alkyl, halogen, hydroxy, oxo, cyano, tetrazolyl, amino, and -C(=O)OR₇ wherein R₇ represents hydrogen or (C₁-C₆)alkyl,
- 10 • m is an integer from 0 to 7 inclusive,
- the group(s) R₂, which may be identical or different independently of each other, is (are) selected from (C₁-C₆)alkyl, halogen, -CN, NO₂, SCF₃, -CF₃, -OCF₃, -NR₇R₈, -OR₈, -SR₈, -SOR₈, -SO₂R₈, -(CH₂)_kSO₂NR₇R₈, -X₇(CH₂)_kC(=O)OR₈, -(CH₂)_kC(=O)OR₈, -X₇(CH₂)_kC(=O)NR₇R₈, -(CH₂)_kC(=O)NR₇R₈, and -X₈-R₂₀ in which:
- 15 - X₇ represents a group selected from oxygen, sulphur optionally substituted by one or two oxygen atoms, and nitrogen substituted by hydrogen or (C₁-C₆)alkyl,
- k is an integer from 0 to 3 inclusive,
 - R₇ and R₈, which may be identical or different independently of each other, are selected from hydrogen and (C₁-C₆)alkyl,
- 20 - X₈ represents a group selected from single bond, -CH₂-, oxygen atom, sulphur atom optionally substituted by one or two oxygen atoms, and nitrogen atom substituted by hydrogen atom or (C₁-C₆)alkyl group,
- R₂₀ represents 5- or 6-membered monocycle aryl, heteroaryl, cycloalkyl, or heterocycloalkyl which is optionally substituted by one or more groups, which may be identical or different, selected from (C₁-C₆)alkyl, halogen, hydroxy and amino, and when the ring is heterocyclic, it comprises from 1 to 4 heteroatoms selected from nitrogen, oxygen and sulphur,

optionally, the racemic forms thereof, isomers thereof, N-oxides thereof, and the pharmaceutically acceptable salts thereof,

it being understood that when no specification are described:

- an aryl group denotes an aromatic monocyclic or bicyclic system containing from 5 to 10 carbon atoms, and in the case of a bicyclic system, one of the ring of which is aromatic in character, and the other ring of which may be aromatic or partially hydrogenated,


- a heteroaryl group denotes an aryl group as described above in which 1 to 4 carbon atoms are replaced by 1 to 4 hetero atoms selected from oxygen, sulfur and nitrogen,

- a cycloalkyl group denotes a monocyclic or bicyclic system containing from 3 to 10 carbon atoms, this system being saturated or partially unsaturated but without aromatic character,

- and a heterocycloalkyl group denotes a cycloalkyl group as defined hereinbefore in which 1 to 4 carbon atoms are replaced by 1 to 4 hetero atoms selected from oxygen, sulfur, and nitrogen.

2- A compound according to claim 1 characterized in that :

- G_2 represents a group selected from $C=O$, $C=S$, $S(O)_{n1}$ in which $n1$ represents an integer from 0 to 2 inclusive, or a group of formula (i/c):



in which the carbon atom with number 1 is attached to the bicycle of the compound of formula (I), Y_1 represents a group selected from oxygen, sulphur, -NH and $-N(C_1-C_6)alkyl$, and Y_2 represents a group selected from oxygen, sulphur, -NH and $-N(C_1-C_6)alkyl$,

- X_1 , X_2 , X_3 , G_1 , n , Z_1 , A , R_1 , m and R_2 are as defined in formula (I),

optionally, the racemic forms thereof, isomers thereof, N-oxides thereof, and the pharmaceutically acceptable salts thereof.

3- A compound according to Claim 1 characterized in that:

- G_2 represents a carbon-carbon triple bond,


- n represents an integer from 1 to 6 inclusive,
- X_1 , X_2 , X_3 , G_1 , Z_1 , A, R_1 , m and R_2 are as defined in formula (I), optionally, the racemic forms thereof, isomers thereof, N-oxides thereof, and the pharmaceutically acceptable salts thereof.

5 4- A compound according to claim 1 characterized in that:

- G_2 represents a carbon-carbon triple bond,
- n is zero,
- Z_1 is absent,
- A represents a group selected from heteroaryl, cycloalkyl, heterocycloalkyl, these groups being 5- or 6-membered monocycle or bicyclic composed of two 5- or 6-membered monocycle,
- X_1 , X_2 , X_3 , G_1 , R_1 , m and R_2 are as defined in formula (I), optionally, the racemic forms thereof, isomers thereof, N-oxides thereof, and the pharmaceutically acceptable salts thereof.

15 5-A compound according to claim 1 characterized in that:

- G_2 represents a carbon-carbon triple bond,
- n is zero,
- Z_1 is absent,
- A represents a phenyl group,
- R_1 represents a hydrogen atom or a group of formula (i/d) :



- ✓ in which p is an integer from 0 to 8 inclusive,
- ✓ Z_2 represents $-CR_{11}R_{12}$ wherein R_{11} and R_{12} , identical or different independently of each other, represent a group selected from hydrogen, (C_1-C_6)alkyl, phenyl, trihalogeno(C_1-C_6)alkyl, halogen, amino, OR_7 , SR_7 and $-C(=O)OR_7$ in which R_7 represents hydrogen or (C_1-C_6)alkyl, and
- wherein when p is greater than or equal to 2, the hydrocarbon chain Z_2 optionally contains one or two isolated or conjugated multiple bonds,

- and/or wherein n is greater than or equal to 2, one of said $-CR_{11}R_{12}$ may optionally be replaced with a group selected from oxygen, $S(O)_{n1}$ in which n1 is as defined hereinbefore, -NH, -N(C₁-C₆)alkyl, and carbonyl,
 - ✓ B represents a phenyl group,
 - ✓ q is an integer from 1 to 7 inclusive,
 - ✓ the group(s) G₃, which may be identical or different independently of each other, is (are) selected from $-(CH_2)_kNR_{13}R_{14}$, $-N(R_{13})C(=O)OR_{14}$, $-N(R_{13})SO_2R_{14}$, $-N(SO_2R_{13})_2$, $-S(O)_{k1}R_{13}$, $-SO_2-N(R_{13})-(CH_2)_{k2}-NR_{14}R_{15}$, $-(CH_2)_kSO_2NR_{13}R_{14}$, $-X_4(CH_2)_kC(=O)OR_{13}$, $-(CH_2)_kC(=O)OR_{13}$, $-C(=O)O-(CH_2)_{k2}-NR_{13}R_{14}$, $-C(=O)O-(CH_2)_{k2}-C(=O)OR_{16}$, $-X_4(CH_2)_kC(=O)NR_{13}R_{14}$, $-(CH_2)_kC(=O)NR_{13}R_{14}$, $-R_{17}-C(=O)OR_{13}$, $-X_5-R_{18}$, $-C(=O)-R_{19}-NR_{13}R_{14}$ and $-X_6-R_{21}$ in which :
 - X₄ represents a group selected from oxygen atom, sulphur atom optionally substituted by one or two oxygen atoms, and nitrogen atom substituted by a hydrogen atom or a (C₁-C₆)alkyl group,
 - k is an integer from 0 to 3 inclusive,
 - k₁ is an integer from 1 to 2 inclusive,
 - k₂ is an integer from 1 to 4 inclusive,
 - R₁₃, R₁₄ and R₁₅, which may be identical or different independently of each other, are selected from hydrogen and (C₁-C₆)alkyl,
 - R₁₆ represents a group selected from (C₁-C₆)alkyl, $-R_{19}-NR_{13}R_{14}$, $-R_{19}-NR_{13}-C(=O)-R_{19}-NR_{14}R_{15}$, and $-C(=O)O-R_{19}-NR_{13}R_{14}$ in which R₁₉ represents a linear or branched (C₁-C₆)alkylene group, and R₁₃, R₁₄ and R₁₅ are as defined hereinbefore,
 - R₁₇ represents a (C₃-C₆)cycloalkyl group,
 - X₅ represents a group selected from single bond, -CH₂-, oxygen atom, sulphur atom optionally substituted by one or two oxygen atoms, and nitrogen atom substituted by hydrogen atom or (C₁-C₆)alkyl group,
 - R₁₈ represents a group selected from heteroaryl, cycloalkyl, heterocycloalkyl, these groups being 5- or 6-membered monocycle or bicyclic composed of two 5- or 6-membered monocycle, which is optionally substituted by one or more groups, which may be identical or different independently of each other, selected from

(C₁-C₆)alkyl, halogen, hydroxy, oxo, cyano, tetrazolyl, amino, and -C(=O)OR₇, wherein R₇ represents hydrogen or (C₁-C₆)alkyl,

- X₆ represents a group selected from -CH₂-, sulphur atom optionally substituted by one or two oxygen atoms, and nitrogen atom substituted by hydrogen atom or (C₁-C₆)alkyl group,


- R₂₁ represents a phenyl group which is optionally substituted by one or more groups, which may be identical or different independently of each other, selected from (C₁-C₆)alkyl, halogen, hydroxy, cyano, tetrazolyl, amino, and -C(=O)OR₇, wherein R₇ represents hydrogen or (C₁-C₆)alkyl,

- X₁, X₂, X₃, G₁, m and R₂ are as defined in formula (I),

optionally, the racemic forms thereof, isomers thereof, N-oxides thereof, and the pharmaceutically acceptable salts thereof.

6- A compound according to Claim 1 characterized in that:

R₁ represent a group of formula (i/d):



wherein Z₂, p, B, G₃ and q are as defined in the compound of formula (I),

optionally, the racemic forms thereof, isomers thereof, N-oxides thereof, and the pharmaceutically acceptable salts thereof.

7- A compound according to Claim 6 characterized in that Z₂ represents a group -CR₁₁R₁₂

20 in which R₁₁ and R₁₂ represents an hydrogen atom,

optionally, the racemic forms thereof, isomers thereof, N-oxides thereof, and the pharmaceutically acceptable salts thereof.

8- A compound according to claim 6 characterized in that p is one,

optionally, the racemic forms thereof, isomers thereof, N-oxides thereof, and the pharmaceutically acceptable salts thereof.

9- A compound according to claim 6 characterized in that B represents a phenyl group, q is equal to 0 or 1, and G₃, when it is present, represents a group selected from OR₁₃, halogen, S(O)_{k1}R₁₃ and (CH₂)_kC(=O)OR₁₃ in which R₁₃ represents an hydrogen atom or a (C₁-C₆)alkyl group, k is zero, and k₁ is two,

5 optionally, the racemic forms thereof, isomers thereof, N-oxides thereof, and the pharmaceutically acceptable salts thereof.

10- A compound according to claim 1 characterized in that G₁ represent a group of formula (i/a) in which R₄ represents a hydrogen atom or a methyl group, or a group of formula (i/b) in which R₄ and R₅, identical, represent each a hydrogen atom or a methyl group, and R₆ represents a hydrogen atom or a methyl group,

10 optionally, the racemic forms thereof, isomers thereof, N-oxides thereof, and the pharmaceutically acceptable salts thereof.

11- A compound according to claim 1 characterized in that X₁ represents a group -CR₃ in which R₃ represents a hydrogen atom, X₂ represents a nitrogen atom or a group -CR₃ in which R₃ represents a hydrogen atom, and X₃ represents a group -CR₃ in which R₃ represents a hydrogen atom,

15 optionally, the racemic forms thereof, isomers thereof, N-oxides thereof, and the pharmaceutically acceptable salts thereof.

12- A compound according to claim 1 characterized in that G₂ represent a carbon-carbon triple bond or a group of formula (i/c) in which Y₁ represents an oxygen atom, and Y₂ represents a group -NH,

20 optionally, the racemic forms thereof, isomers thereof, N-oxides thereof, and the pharmaceutically acceptable salts thereof.

13- A compound according to claim 1 characterized in that Z₁ represents -CR₉R₁₀ in which R₉ and R₁₀ represent each a hydrogen atom, and n is one,

25 optionally, the racemic forms thereof, isomers thereof, N-oxides thereof, and the pharmaceutically acceptable salts thereof.

14- A compound according to claim 1 characterized in that A represents a group selected from phenyl and pyridyl, m is equal to zero or one, and R₂ represents a (C₁-C₆)alkoxy group or a hydrogen atom,
optionally, the racemic forms thereof, isomers thereof, N-oxides thereof, and the
5 pharmaceutically acceptable salts thereof.

15- A compound according to claim 1, which is selected from:

- 3-(4-methoxy-benzyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid 4-methoxy-benzylamide
- 3-(4-methoxy-benzyl)-2-methyl-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid 4-methoxy-benzylamide, hydrochloride
- 3-(4-methoxy-benzyl)-1-methyl-4-oxo-1,2,3,4-tetrahydro-quinazoline-6-carboxylic acid 4-methoxy-benzylamide
- 3-(4-methoxy-benzyl)-1,2,2-trimethyl-4-oxo-1,2,3,4-tetrahydro-quinazoline-6-carboxylic acid 4-methoxy-benzylamide
- 4-[6-(4-methoxy-benzylcarbamoyl)-4-oxo-1,4-dihydro-2H-quinazolin-3-ylmethyl]-benzoic acid
- 4-[6-(4-methoxy-benzylcarbamoyl)-1-methyl-4-oxo-1,4-dihydro-2H-quinazolin-3-ylmethyl]-benzoic acid methyl ester
- 4-[6-(4-methoxy-benzylcarbamoyl)-1-methyl-4-oxo-1,4-dihydro-2H-quinazolin-3-ylmethyl]-benzoic acid,
- 3-(4-fluoro-benzyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid 3-methoxy-benzylamide
- 3-(4-methanesulfonyl-benzyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid 4-methoxy-benzylamide
- 4-Oxo-3-[4-(pyrrolidine-1-sulfonyl)-benzyl]-3,4-dihydro-quinazoline-6-carboxylic acid 4-methoxy-benzylamide
- 4-[6-(3-methoxy-benzylcarbamoyl)-4-oxo-4H-quinazolin-3-ylmethyl]-benzoic acid,
- 3-(4-fluoro-benzyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide,
- 3-(3-fluoro-benzyl)-4-oxo-3,4-dihydro-pyrido[3,4-d]pyrimidine-6-carboxylic acid 3-methoxy-benzylamide,

- 3-(3-fluoro-benzyl)-4-oxo-3,4-dihydro-pyrido[3,4-d]pyrimidine-6-carboxylic acid 4-methoxy-benzylamide
- 3-(3,4-Difluoro-benzyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide and
- 5 - 3-(3,4-Difluoro-benzyl)-4-oxo-3,4-dihydro-quinazoline-6-carboxylic acid 4-methoxy-benzylamide.

16- A compound according to claim 1, which is selected from:


- 3-(4-fluorobenzyl)-6-(3-phenyl-prop-1-ynyl)-3H-quinazolin-4-one,
- methyl 4-[4-oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzoate,
- 10 - 4-[4-oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzoic acid,
- 3-(4-fluorobenzyl)-6-(3-phenyl-prop-1-ynyl)-3H-pyrido[3,4-d]pyrimidin-4-one,
- methyl 4-[6-(3-phenyl-prop-1-ynyl)-4-oxo-4H-pyrido[3,4-d]pyrimidin-3-ylmethyl]-benzoate,
- 4-[6-(3-phenyl-prop-1-ynyl)-4-oxo-4H-pyrido[3,4-d]pyrimidin-3-ylmethyl]-benzoic acid,
- 15 - 4-[4-oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazoline-3-ylmethyl]-benzoic acid,
- 4-{6-[3-(4-methoxy-phenyl)-prop-1-ynyl]-4-oxo-4H-quinazoline-3-ylmethyl}-benzoic acid,
- 4-[4-oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazoline-3-ylmethyl]-benzamide
- 20 - 3-[(3,5-difluoro-4-hydroxy)-benzyl]-6-(3-phenyl-prop-1-ynyl)-3H-quinazolin-4-one
- 4-[6-(3-Imidazol-1-yl-prop-1-ynyl)-4-oxo-4H-quinazolin-3-ylmethyl]-benzoic acid
- 4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzenesulfonamide
- 4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzonitrile
- 3-(3-Chloro-benzyl)-6-(4-phenyl-but-1-ynyl)-3H-quinazolin-4-one
- 25 - 3-(3-Chloro-benzyl)-6-(3-phenyl-prop-1-ynyl)-3H-quinazolin-4-one
- 4-[4-Oxo-6-(3-pyrazol-1-yl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzoic acid
- 6-(3-Phenyl-prop-1-ynyl)-3-[4-(1H-tetrazol-5-yl)-benzyl]-3H-quinazolin-4-one
- 3-(3,4-Difluoro-benzyl)-6-[3-(pyridin-4-yloxy)-prop-1-ynyl]-3H-quinazolin-4-one
- 3-(3,4-Difluoro-benzyl)-6-[3-(4-methoxy-phenyl)-prop-1-ynyl]-3H-quinazolin-4-one
- 30 - N-{4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-phenyl}-acetamide
- 3-(3,4-Difluoro-benzyl)-6-(3-phenyl-prop-1-ynyl)-3H-quinazolin-4-one

- 3-(4-Acetyl-benzyl)-6-[3-(4-methoxy-phenyl)-prop-1-ynyl]-3H-quinazolin-4-one
- 6-(3-Phenyl-prop-1-ynyl)-3-pyridin-4-ylmethyl-3H-quinazolin-4-one and
- 6-[3-(4-Methoxy-phenyl)-prop-1-ynyl]-3-pyridin-4-ylmethyl-3H-quinazolin-4-one.

5 17- A compound according to claim 1, which is selected from:


- Methyl 4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl] benzoate
- 4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzoic acid
- 4-[6-(3-Methoxy-benzylcarbamoyl)-4-oxo-4H-quinazolin-3-ylmethyl] benzoic acid
- 4-{6-[3-(4-Methoxy-phenyl)-prop-1-ynyl]-4-oxo-4H-quinazoline-3-ylmethyl}-benzoic acid
- 3-(3-Fluoro-benzyl)-4-oxo-3,4-dihydro-pyrido[3,4-d]pyrimidine-6 carboxylic acid 3-methoxy-benzylamide
- 3-(3-Fluoro-benzyl)-4-oxo-3,4-dihydro-pyrido[3,4-d]pyrimidine-6 carboxylic acid 4-methoxy-benzylamide
- 4-[6-(3-Imidazol-1-yl-prop-1-ynyl)-4-oxo-4H-quinazolin-3-ylmethyl]-benzoic acid
- 4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzenesulfonamide
- 4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-benzonitrile
- 6-(3-Phenyl-prop-1-ynyl)-3-[4-(1H-tetrazol-5-yl)-benzyl]-3H-quinazolin-4-one
- 3-(3,4-Difluoro-benzyl)-6-[3-(pyridin-4-yloxy)-prop-1-ynyl]-3H-quinazolin-4-one
- 3-(3,4-Difluoro-benzyl)-6-[3-(4-methoxy-phenyl)-prop-1-ynyl]-3H-quinazolin-4-one
- N-{4-[4-Oxo-6-(3-phenyl-prop-1-ynyl)-4H-quinazolin-3-ylmethyl]-phenyl}-acetamide
- 3-(4-Acetyl-benzyl)-6-[3-(4-methoxy-phenyl)-prop-1-ynyl]-3H-quinazolin-4-one
- 6-(3-Phenyl-prop-1-ynyl)-3-pyridin-4-ylmethyl-3H-quinazolin-4-one and
- 6-[3-(4-Methoxy-phenyl)-prop-1-ynyl]-3-pyridin-4-ylmethyl-3H-quinazolin-4-one.

25 18- A process for the preparation of compounds according to claim 1 which uses as starting material a compound of formula (II):




in which X_1 , X_2 , X_3 , and Y_1 have the same definitions as the compound of formula (I) in claim 1, and T represents a group (C_1-C_6)alkyl,

compound of formula (II) which is treated with a compound of formula (III):



5


in which Z_1 , Y_2 , R_2 , A, n and m have the same definitions as the compound of formula (I), by activating the acid function with an activator, in the presence of diisopropylethylamine and a solvent, to yield the compound of formula (IV) :



10 in which X_1 , X_2 , X_3 , Y_1 , T, Z_1 , Y_2 , R_2 , A, n and m are as defined hereinbefore,

compound of formula (IV) in which the ester group is hydrolyzed and the subsequently compound obtained is then treated with an activator in the presence of a base and a primary amine with the general formula R_1-NH_2 in which R_1 is as defined in the compound of formula (I),

15 to yield the compound of formula (V) :




in which X_1 , X_2 , X_3 , Y_1 , Y_2 , Z_1 , R_2 , R_1 , A, n and m are as defined hereinbefore,

which compound of formula (V) is treated :

- either with triethyl orthoformate under heating condition, to yield the compound of


20 formula (I/a), which is a particular case of the compound of formula (I):

78




in which X_1 , X_2 , X_3 , Y_1 , Y_2 , Z_1 , R_2 , R_1 , A , n and m are as defined hereinbefore,

- or under heating condition in the presence of acid, with a compound of formula (VI):




- 5 in which R_4 has the same definition as the compound of formula (I),
to yield the compound of formula (I/b), which is a particular case of the compound of
formula (I):




in which X_1 , X_2 , X_3 , Y_1 , Y_2 , Z_1 , R_2 , R_1 , R_4 , A , n and m are as defined hereinbefore,

- 10 • or with a compound of formula (VII) in basic condition:



in which R_4 and R_5 have the same definition as the compound of formula (I),

- to yield the compound of formula (I/c), which is a particular case of the compound of
formula (I):




- 15 in which X_1 , X_2 , X_3 , Y_1 , Y_2 , Z_1 , R_2 , R_1 , R_4 , R_5 , A , n and m are as defined hereinbefore,

which compound of formula (I/c) is optionally treated with a hydride, in the presence of a compound of formula (VIII):



in which R_6 has the same definition as the compound of formula (I),


- 5 to yield the compound of formula (I/d), which is a particular case of the compound of formula (I):



in which X_1 , X_2 , X_3 , Y_1 , Y_2 , Z_1 , R_2 , R_1 , R_4 , R_5 , R_6 , A , n and m are as defined hereinbefore,

10 compounds of formulae (I/a), (I/b), (I/c) and (I/d) constitute some compounds of the invention, which are purified, where appropriate, according to a conventional purification technique, which are separated, where appropriate, into their different isomers according to a conventional separation technique, and which are converted, where appropriate, into addition salts thereof with a pharmaceutically-acceptable acid or base, or into N-oxide thereof.


- 15 19- A process for the preparation of compounds according to claim 1 which uses as starting material a compound of formula (X):



in which X_1 , X_2 , and X_3 have the same definitions as the compound of formula (I), and Hal represents a halogen atom,


- 20 which compound of formula (X) is treated in a first step with a derivate of phosgene to yield the compound of formula (XI):

80



in which X_1 , X_2 , X_3 and Hal are as defined hereinbefore,


which compound of formula (XI) is treated in basic medium with a primary amine of general formula $R_1\text{-NH}_2$ in which R_1 has the same definition as in the compound of formula (I),
5 to yield the compound of formula (XII):



in which X_1 , X_2 , X_3 , R_1 and Hal are as defined hereinbefore,


10 which compound of formula (XII) is treated:

- either with triethyl orthoformate under heating condition, to yield the compound of formula (XIII/a) :




in which X_1 , X_2 , X_3 , R_1 and Hal are as defined hereinbefore,

15 • or under heating conditions in the presence of an acid, with a compound of formula (VI):




in which R_4 has the same definition as the compound of formula (I),
to yield the compound of formula (XIII/b) :

81




in which X_1 , X_2 , X_3 , Hal, R_1 , and R_4 are as defined hereinbefore,

- or with a compound of formula (VII) in basic conditions:



5 in which R_4 and R_5 have the same definition as the compound of formula (I),

to yield the compound of formula (XIII/c) :



in which X_1 , X_2 , X_3 , Hal, R_1 , R_4 , and R_5 are as defined hereinbefore,


which compound of formula (XIII/c) is optionally treated with a hydride, in the presence of

10 a compound of formula (VIII):




in which R_6 has the same definition as the compound of formula (I), and Hal is a halogen atom,

to yield the compound of formula (XIII/d), which is a particular case of the compound of formula (I):




in which X_1 , X_2 , X_3 , Hal, R_1 , R_4 , R_5 and R_6 are as defined hereinbefore,

all compounds of formulae (XIII/a), (XIII/b), (XIII/c) and (XIII/d) constitute the compound of formula (XIII/e):




in which X_1 , X_2 , X_3 , Hal, R_1 and G_1 are as defined in the compound of formula (I),

5 compound of formula (XIII/e) which is treated under conditions of palladium-catalyzed alkynylation with a compound of formula (XIV):



in which Z_1 , R_2 , A , n and m have the same definitions as the compound of formula (I),

10 to yield the compound of formula (I/e), which is a particular case of the compound of formula (I):




in which X_1 , X_2 , X_3 , R_1 , G_1 , Z_1 , R_2 , A , n and m have the same definitions as the compound of formula (I),

15 compounds of formula (I/e) constitute some compounds of the invention, which are purified, where appropriate, according to a conventional purification technique, which are separated, where appropriate, into their different isomers according to a conventional separation technique, and which are converted, where appropriate, into addition salts thereof with a pharmaceutically-acceptable acid or base, or into N-oxide thereof.


20- A process for the preparation of compounds according to claim 1 wherein it is used as starting material a compound of formula (XIII/e)

83




in which X_1 , X_2 , X_3 , R_1 and G_1 are as defined in the compound of formula (I), and Hal is a halogen atom,

compound of formula (XIII/e) which is condensed, in the presence of dichlorobis(triphenylphosphine)palladium, copper iodide and *N,N'*-diisopropylethylamine in dimethylformamide, on a compound of formula (XV) :




in which Z_1 , R_2 , A , n and m have the same definitions as the compound of formula (I),

to yield the compound of formula (I/e), which is a particular case of the compound of formula (I):




in which X_1 , X_2 , X_3 , R_1 , G_1 , Z_1 , R_2 , A , n and m have the same definitions as the compound of formula (I).

21 - A process for the preparation of compounds according to claim 1, which uses as starting material a compound of formula (XIII/e) :




in which X_1 , X_2 , X_3 , R_1 and G_1 are as defined in the compound of formula (I), and Hal is a halogen atom,

compound of formula (XIII/e) which is reacted with carbon monoxide in an alkaline medium in the presence of a protic solvent and a catalytic amount of palladium, to yield the compound of formula (XVI):



5 in which X_1 , X_2 , X_3 , R_1 and G_1 are as defined in the compound of formula (I),

compound of formula (XVI) which is hydrolyzed under basic medium to yield the compound of formula (XVII):




10 in which X_1 , X_2 , X_3 , R_1 and G_1 are as defined in the compound of formula (I),

compound of formula (XVII) which is condensed under basic medium in the presence of a Mukayama reagent, on the compound of formula (XVIII):



15 in which Z_1 , R_2 , A , n and m have the same definitions as the compound of formula (I),

to yield the compound of formula (I/f), which is a particular case of the compound of formula (I):




20 in which X_1 , X_2 , X_3 , Z_1 , R_2 , R_1 , A , n and m are as defined hereinbefore,

compounds of formula (I/f) constitute some compounds of the invention, which are purified, where appropriate, according to a conventional purification technique, which are separated, where appropriate, into their different isomers according to a conventional


separation technique, and which are converted, where appropriate, into addition salts thereof with a pharmaceutically-acceptable acid or base, or into N-oxide thereof.

22 – A process for the preparation of compounds according to claim 1, which uses as starting material a compound of formula (XIX) :




in which Hal represents a halogen atom,

compound of formula (XIX) which is heated in the presence of formamidine acetate in a polar solvent, to yield compound of formula (XX):



in which Hal is as defined hereinbefore,


compound of formula (XX) which is treated in basic medium with a compound of formula R₁-Hal, in which R₁ is as defined in the compound of formula (I) and Hal represents a halogen atom, to yield the compound of formula (XXI):



in which Hal and R₁ are as defined hereinbefore,

compound of formula (XXI) which is reacted with carbon monoxide under basic medium in the presence of an alcoholic solvent and a catalytic amount of palladium, to yield the compound of formula (XXII):

86



in which R₁ is as defined hereinbefore,

compound of formula (XXII) which is condensed, in the presence of trimethylaluminium,


5 with a compound of formula (XVIII):



in which Z₁, R₂, A, n and m have the same definitions as the compound of formula (I),

to yield the compound of formula (I/g), which is a particular case of the compound of

10 formula (I):



in which Z₁, R₂, R₁, A, n and m are as defined hereinbefore,

compounds of formula (I/g) constitute some compounds of the invention, which are

purified, where appropriate, according to a conventional purification technique, which are

15 separated, where appropriate, into their different isomers according to a conventional

separation technique, and which are converted, where appropriate, into addition salts

thereof with a pharmaceutically-acceptable acid or base, or into N-oxide thereof.

23- A method for treating a living body afflicted with a disease where the inhibition of type -13 matrix metalloprotease is involved, comprising the step of administering to the living 20 body an amount of a compound of claim 1 which is effective for alleviation of said conditions.

24- A method for treating a living body afflicted with a disease selected from arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel

disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary disease, age-related macular degeneration, and cancers, comprising the step of administering to the living body an amount of a compound of claim 1 which is effective for alleviation of said conditions.

- 5 25- A pharmaceutical composition comprising as active ingredient an effective amount of a compound as claimed in claim 1, alone or in combination with one or more pharmaceutically-acceptable excipients or carriers.
- 10 26- A pharmaceutical composition useful in the method of Claim 23 comprising as active ingredient an effective amount of a compound as claimed in claim 1, together with one or more pharmaceutically-acceptable excipients or carriers.
- 27- A pharmaceutical composition useful in the method of Claim 23 comprising as active ingredient an effective amount of a compound as claimed in claim 16, together with one or more pharmaceutically-acceptable excipients or carriers.
- 15 28- A pharmaceutical composition useful in the method of Claim 23 comprising as active ingredient an effective amount of a compound as claimed in claim 17, together with one or more pharmaceutically-acceptable excipients or carriers.
- 29- Use of a compound according to Claim 1, for the preparation of a medicinal product intended for treating a disease involving therapy by inhibition of type-13 matrix metalloproteases.
- 20 30- Use according to Claim 29, characterized in that the disease is arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary disease, age-related macular degeneration, and cancers.
- 31- Use according to Claim 30, characterized in that the disease is arthritis.

32- Use according to Claim 30, characterized in that the disease is osteoarthritis.

33- Use according to Claim 30, characterized in that the disease is rheumatoid arthritis.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 September 2003 (18.09.2003)

PCT

(10) International Publication Number
WO 03/076417 A3

(51) International Patent Classification⁷: **C07D 239/91, 471/04, A61K 31/5025, 31/505, A61P 29/00, C07D 401/06, 401/10, 401/12 // (C07D 471/04, 239:00, 221:00) (C07D 401/06, 239:00, 233:00) (C07D 401/10, 257:00, 239:00) (C07D 401/12, 239:00, 213:00)**

(21) International Application Number: PCT/EP03/02277

(22) International Filing Date: 6 March 2003 (06.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/EP02/03240 8 March 2002 (08.03.2002) EP

(71) Applicant (for all designated States except US):
WARNER-LAMBERT COMPANY LLC [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **GAUDILLIERE, Bernard [FR/FR]; 28, rue de Zilina, F-92000 Nanterre (FR). JACOBELLI, Henry [FR/FR]; 65, avenue du Général de Gaulle, F-91550 Paray Vieille Poste (FR). KOSTLAN, Catherine [US/US]; 9876 Moon Road, Saline, MI 48176 (US). LI, Jack [US/US]; 258 Village Green Blvd., #101, Ann Arbor, MI 48105 (US). YUE, Wen-Song [US/US]; 6015 Gabrielle Ave, Ann Arbor, MI 48103 (US).**

(74) Agents: **HIRSCH, Denise et al.; Pfizer, Global Research and Development, Fresnes Laboratories, 3-9, rue de la Loge, B.P. 100, F-94265 Fresnes Cedex (FR).**


(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,

[Continued on next page]


(54) Title: OXO-AZABICYCLIC COMPOUNDS




(I)



(i/a) (i/b)



(i/c)



(i/d)

(57) Abstract: A compound selected from those of formula (I) wherein: X₁, X₂, and X₃, represent N or -CR₃ in which R₃ is as described in the description, G₁ represents a group selected from those of formulae (i/a) and (i/b) in which R₄, R₅, and R₆ are as defined in the description, G₂ represents a group selected from carbon-carbon triple bond, -CH=C=CH-, C=O, C=S, S(O)_{n1} in which n1 represents an integer from 0 to 2 inclusive, or a group of formula (i/c) in which Y₁ represents O, S, -NH or -Nalkyl, and Y₂ represents O, S, -NH or -Nalkyl, n is an integer from 0 to 6 inclusive, and m is an integer from 0 to 7 inclusive, Z₁ represents -CR₉R₁₀, wherein R₉ and R₁₀ are as defined in the description, A represents a ring system, R₁ represents a group selected from H, alkyl, alkenyl, alkynyl, optionally substituted and the group of formula (i/d) in which p, Z₂, B, q and G₃ are as defined in the description and optionally, its optical isomers, N-oxide, and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same are useful as specific inhibitors of type-13 matrix metalloprotease.

WO 03/076417 A3



SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

- (84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG,

Published:

- with international search report

(88) Date of publication of the international search report:

13 November 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/02277

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07D239/91 C07D471/04 A61K31/5025 A61K31/505 A61P29/00
 'C07D401/06 C07D401/10 C07D401/12 // (C07D471/04, 239:00, 221:00), (C07D401/06, 239:00, 233:00), (C07D401/10, 257:00, 239:00),

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LIVERTON N J ET AL: "Nonpeptide glycoprotein IIb/IIIa inhibitors: substituted quinazolinediones and quinazolinones as potent fibrinogen receptor antagonists" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 8, no. 5, 3 March 1998 (1998-03-03), pages 483-486, XP004136889 ISSN: 0960-894X Compound 2, abstract — —	1, 30-33



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

21 May 2003

Date of mailing of the international search report

04/06/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patenttaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

Goss, I

INTERNATIONAL SEARCH REPORT

Inte ial Application No

PCT/EP 03/02277

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 (C07D401/12, 239:00, 213:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>REITER L A ET AL: "Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocket" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 9, no. 2, 18 January 1999 (1999-01-18), pages 127-132, XP004152585 ISSN: 0960-894X the whole document</p> <p>—</p> <p>WO 98 26664 A (BELLINA RUSSELL FRANK ;CHRISTENSEN JOEL ROBERT (US); FAWZI MAGED M) 25 June 1998 (1998-06-25) cited in the application Index table A, pages 65 to 67</p> <p>—</p> <p>—</p>	1, 30-33
A		1

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

21 May 2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

GOSS, I

INTERNATIONAL SEARCH REPORT

Inte nal Application No

PCT/EP 03/02277

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	J.K. PADIA, H. CHILVERS, P.DAUM ET AL.: "Design and synthesis of novel nonpeptide CCK-B receptor antagonists" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 7, no. 7, 1997, pages 805-810, XP002222965 the whole document —	1,30-33
P,X	WO 02 064572 A (ANDRIANJARA CHARLES ;GAUDILLIERE BERNARD (FR); JACOBELLI HENRI (FR) 22 August 2002 (2002-08-22) the whole document —	1
P,A	WO 02 064080 A (ANDRIANJARA CHARLES ;ORTWINE DANIEL FRED (US); PAVLOVSKY ALEXANDER) 22 August 2002 (2002-08-22) Claim 1, Examples —	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte

al Application No

PCT/EP 03/02277

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 9826664	A	25-06-1998	AU BR EP JP WO	5380398 A 9714222 A 0946095 A1 2002513394 T 9826664 A1		15-07-1998 18-04-2000 06-10-1999 08-05-2002 25-06-1998
WO 02064572	A	22-08-2002	WO US	02064572 A1 2002193377 A1		22-08-2002 19-12-2002
WO 02064080	A	22-08-2002	WO	02064080 A2		22-08-2002